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 ABSTRACT 
On a cellular level cancer is described as abnormal cellular growth resulting from uncontrolled 
cellular proliferation and reduced apoptosis. Cancer is seen as a non-discriminative disease, 
therefore exhibiting high incidence and mortality rates. Additionally, cancer is classified as a 
global burden in both economically developed and developing countries. The 37kDa/67kDa 
laminin receptor (LRP/LR) is seen to be over-expressed in tumor cells when compared to their 
normal cell counterparts. This receptor has been implicated in several tumourigenic processes 
such as cell migration and adhesion but importantly for the present study, the maintenance of 
cellular viability and the evasion of apoptosis. The aim of the present study was to investigate the 
role of LRP/LR on the cellular viability of early (A375) and late stage (A375SM) malignant 
melanoma cells. Flow cytometry revealed that both malignant melanoma cell lines exhibit high 
cell surface LRP/LR levels and with further analysis using median fluorescence intensity, it was 
observed that A375SM cells contain approximately 86% more cell-surface LRP/LR than A375 
cells. In addition, western blotting and densitometric analysis suggested that A375SM cells 
contain 60% more total LRP/LR levels than A375 cells. Furthermore, western blot analysis 
revealed that targeting the mRNA of the 37kDa LRP using a LRP-specific siRNA (Dharmacon 
ON-TARGET Human RPSA) in A375 and A375SM cells led to significant down-regulation of 
77% and 72% in LRP expression, respectively. Consequently, MTT assays showed that LRP 
down-regulation led to significant reductions of 47% and 61% in the viability of A375 and 
A375SM cells, respectively. An alternative LRP-specific siRNA (Mission esiRNA-RPSA) was 
used in order to confirm specificity and to exclude any off-target effects of Dharmacon ON-
TARGET Human RPSA for LRP. Confocal microscopy with the addition of the Airyscan 
processing tool indicated nuclear morphological changes suggestive of apoptotic induction in the 
form of cell death occurring in both malignant melanoma cell lines post LRP down-regulation. 
Annexin-V/PI assays confirmed this observation, by revealing that A375 and A375SM cells 
underwent apoptotic induction post LRP down-regulation in comparison to the untreated cells. 
Additionally, caspase-3 activity assays revealed that both cell lines experienced apoptotic 
induction after siRNA-mediated down-regulation of LRP. Caspase-8 and -9 activity assays 
suggested that post LRP down-regulation; A375 cells undergo apoptosis solely via the extrinsic 
pathway, while A375SM cells are thought to undergo apoptosis via the intrinsic pathway. 
According to Munien et al, 2017 [137], application of the anti-LRP/LR specific antibody IgG1-
iS18 has led to a significant reduction in metastatic potential of A375 and A375SM malignant 
melanoma cells in vitro. Therefore the aim of the present in vivo study was to further investigate 
the significance of blocking LRP/LR with the IgG1-iS18 antibody and how this will be effective 
in the treatment of malignant melanoma in vivo using a MF-1 nude mice model. The mice were 
divided into three groups; with three mice each. This was followed by treatment of group 1 with 
0.885mg/ml of the IgG1-iS18 antibody intraperitoneally, twice a week, group 2 was 
administered with the Phosphate Buffered Saline (PBS) vehicle control solution and the last 
group remained untreated. The results of this pilot study indicated that three of the nine mice 
developed external tumour formation; one of the mice being from the untreated group with a 
tumour volume larger than the other two mice which were from the IgG1-iS18 treatment group. 
When comparing the tumour formation between the untreated and treated group, there was a 
large reduction in tumour weight and volume. To conclude, LRP/LR plays a critical role in the 
maintenance of tumor cellular viability and metastasis, recommending this receptor as a 
promising therapeutic target and proposing the potential use of siRNA technology as well as the 
IgG1-iSi8 antibody for the treatment of malignant melanoma. 
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Chapter 1: Introduction 
1. Cancer 
 
1.1 Epidemiology, diagnosis and treatment 
Cancer is characterized as the rapid establishment of abnormal cells that grow beyond normal 
measures thus invading and spreading to distant organs in the body [1]. Cancer is seen to be one 
of the leading causes of mortality and morbidity worldwide, accounting for 8.8 million deaths in 
2015 [1] and according to the World Cancer Research Fund (WCRF), 14.1 million new cancer 
cases were reported worldwide in 2012, of which 8 million occurred in economically developing 
countries (82% of the world’s population). The estimated number of cancer deaths in 2012 was 
8.2 million, and following this pattern of occurrence, it was estimated that the number of 
reported cancer cases will increase to 24 million by the year 2035 with a corresponding 13 
million cancer-related deaths [2]. 
Furthermore, cancer incidence rates are expected to increase by 70% over the next 2 decades, 
especially in economically developed countries where it is implicated as the primary cause of 
death. Similarly, in economically developing countries, cancer is identified as the second leading 
cause of death [1].  Transformation of normal cells into the tumourigenic state is a multistep 
process [1]. These changes occur as a result of the interaction between genetic factors and 
external factors such as physical carcinogens which include ultraviolet radiation and ionizing 
radiation, chemical carcinogens such as tobacco smoke, biological components such as viral or 
bacterial infections as well as the aging and growth of the world population [1].  
The most commonly diagnosed cancers worldwide are breast cancer in females and lung cancer 
in males [1] and in 2002, 63,800 new cases of cancer were diagnosed in South Africa and 44,200 
cancer deaths reported [3].   
The present study focuses on early (A375) and late (A375SM) stage malignant melanoma which 
was ranked 19
th
 worldwide in 2012 contributing to 1.6% of the total number of cases diagnosed 
(Fig.1) [4]. Malignant melanoma is the most dangerous and deadly form of skin cancer, 
accounting for approximately 74% of skin cancer related deaths [4]. According to the National 
Cancer Registry, in South Africa in 2010, 551 males and 509 females were diagnosed with 
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melanoma. These statistics exemplify the urgent need to develop novel therapeutic strategies to 
combat this deadly form of skin-cancer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The number of worldwide cancer cases diagnosed in 2012. 
(http://www.wcrf.org/int/cancer-facts-figures/worldwide-data).  
A significant proportion of the worldwide cancer burden is lifestyle related and deaths occurring 
thereof may be prevented through the application of existing cancer control knowledge, by 
implementing programs for tobacco control, vaccinations as well as public health campaigns 
encouraging physical activity and healthier lifestyle behavior [1]. Early diagnosis of cancer is 
also pivotal to one’s health, thus allowing for a higher prospect of recovery and the prevention of 
metastasis and resultant formation of secondary, tertiary and quaternary tumors at distant sites in 
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the body [5]. Imaging techniques provide an image of a visible tumor and it is the most common 
method for cancer detection and subsequent diagnosis. These include Magnetic Resonance 
Imaging (MRI), X-rays, CT scans and ultrasound [6]. Cancer diagnosis can also be performed 
via the use of biopsies, genetic testing as well as fluorescent in situ hybridisation (FISH) [7].  
Tumor formation is not exclusive to a particular site and the course of treatment depends on its 
location, the type of cancer and the state of advancement [6]. Surgery is considered the first 
treatment for the removal of solid, benign tumors in early stage cancers [6]. Other treatments 
include radiation, which kills cancer cells by damaging the cell’s DNA, thereby preventing its 
replication [6]. Chemotherapy is another treatment option; targeting rapidly growing cells i.e. 
cancer cells [6]. More advanced therapeutics include gene therapy, viral therapy and 
immunotherapy [7]. 
1.2 Malignant melanoma  
1.2.1 Characterization 
Malignant melanoma has a lower incidence rate than other cancer types but is the most 
dangerous form of skin cancer as it causes the greatest number of skin-cancer related deaths 
worldwide if left untreated. Malignant melanoma is metastatic, and has the ability to invade into 
the skin, enter the blood stream or lymphatic system and spread to other parts of the body such as 
the lungs, liver, bones and brain thus causing death. The global incidence of malignant 
melanoma continues to increase, with 1 in every 3 cancer type diagnosed being skin cancer [8]. 
Malignant melanoma occurs within the skin, an organ consisting two layers; the epidermis (outer 
layer) and the dermis (underneath) as seen in Figure 2. However, the cells which become 
cancerous are known as the melanocytes (pigment-producing cells) and they are located in the 
bottom layer of the skin’s epidermis, more specifically in the stratum basale. Neoplastic tumors 
or neoplasms develop from these melanocytes which are cancerous [9]. Alterations in several 
molecular pathways have been linked to the distinct characteristics of malignant melanoma and 
have been reported to include: tyrosine kinase receptor (TKR) pathway, Ras/Raf, MEK/ERK 
pathway, PI3K/Akt/ PTEN/ mTOR pathway, cell cycle regulation pathways, programmed cell 
death pathways, common apoptosis effectors, protein chaperoning and degradation [10].   
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Figure 2: The structure of the skin. The melanocytes are the pigment-producing cells situated 
in the bottom layer of the skin’s epidermis, more specifically in the stratum basale. These cells 
become cancerous in the case of malignant melanoma (http://www.cancerresearchuk.org/).  
1.2.2 Signs, symptoms and risk factors 
Malignant melanoma can develop anywhere on the human body, however they most often 
develop in areas that are exposed to sunlight, such as the legs, arms, face and back. Melanoma 
can however be found in areas that do not receive as much sun exposure, such as the soles of the 
feet, palms as well as the fingernail bed and this is most commonly observed in darker skinned 
individuals. The first signs and symptoms that arise with melanoma are the changes in an 
existing mole or the developmemt of a new pigment or unusual- looking growth on the skin 
according to the ABCDEs of melanoma [9] (Fig. 3).  
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Figure 3: The ABCDEs of melanoma. The signs and symptoms that may assist in the early 
detection of the disease according to the symmetry, border, colour and diamter of the mole 
present on the skin. Obtained from (http://www.melanomauk.org.uk/wp-
content/uploads/2016/11/ABCDE-Melanoma.png) 
One of the main risk factors for malignant melanoma is high exposure to ultraviolet light 
from direct sunlight or from sunbeds. Other risk factors include: many  moles present on the 
skin,  having fair skin that burns easily and does not tan, a history of sunburn especially in 
childhood or adolescence, previously diagnosed with skin cancer or melanoma, a family 
history of melanoma or other skin cancers and a weak immune system [11].   
1.2.3 Diagnosis and staging 
Melanoma can be diagnosed by observing the natural behaviour of the skin but a more 
efficient method of diagnosis includes a biopsy, in which all or a part of the suspicious mole 
or growth is removed and analysed. The next step after diagnosis is to determine the extent 
(stage) of the cancer. The stage of melanoma describes how deeply it has ulcerated into the 
skin, the thickness of the melanoma and whether it has spread to distant sites in the body 
[11].  Melanoma can be staged according to four different systems however,  in this 
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particular case the number stages will be used to describe the five main stages of melanoma 
(Fig. 4). Stage 0 (in situ) melanoma describes the location of the tumor being limited to the 
outer layer of the skin without the ability to spread, at this stage the tumor can be surgically 
removed. Stage 1 (A and B) is considered early stage melanoma characterized by a growth 
of less than 2mm thick. Stage 2 (A, B and C) melanoma is charaterised by a thickness of 
more than 2 mm without any signs of  spreading to the lymph nodes or other parts of the 
body. Stage 3 (A, B and C) melanoma has now spread to nearby lymph nodes and has to be 
removed. Stage 4 melanoma is the advanced/ late stage and the cancer has now spread to 
other parts of the body, distant from the primary site of origin and to nearby lymph nodes 
[11].     
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The numerical staging of melanoma. At stage 0, the tumor is confined to the 
outer layer of the skin (epidermis). At stage 1, the tumor is less than 2mm thick  with or 
without ulceration (breakdown of the skin layer over the site of the melanoma). At stage 2, 
the tumor is greater than 2 mm thick with or without ulceration. At stage 3 and 4, the tumor 
7 
 
has spread to the lymph nodes and other organs, respectively (http://www.hlifestyle.net/wp-
content/uploads/2015/05/Stage-0-4-melanoma-layers-diagram-Medium.jpg).   
1.2.4 Treatment 
The most effective treatment regime for malignant melanoma will depend on the size and 
stage of the cancer as well as the state of the individual’s health and immune system. The 
treatment for early stage melanoma includes surgery and therefore removal of the cancerous 
mole and a section of the surrounding normal skin. No further treatment is usually required 
at this stage as the melanoma is confined to the epidermis without further ulceration into the 
skin and has not metastasised. Medium stage melanoma (stage 2 and 3) requires surgical 
removal, followed by an additional operation referred to as a wide local excision to remove 
more tissue and possible melanoma cells that may have been left behind in the area. In 
conjuction to surgery, a sentinel node biopsy test may be performed to determine whether 
the melanoma cells have metastasised into the nearby lymph nodes [11]. For advanced stage 
melanoma, a combination of treatment regimes may be employed. The treatments include: 
chemotherapy and radiotherapy which may help shrink the melanoma and relieve symptoms, 
biological therapies such as interferon and interleukin 2 which may assist in shrinking and 
controlling the melanoma for a short period of time [11].    
1.3 Cancer  
       1.3.1 Molecular mechanism of cancer 
       Cancer is defined as the uncontrolled proliferation of cells due to the diminished levels of 
apoptosis or programmed cell death, thus resulting in abnormal cellular growth [12, 13]. In 
the cancerous state, damaged, old or abnormal cells survive whilst new cells divide 
uncontrollably to form growths referred to as either a malignant tumor (invasive) or a benign 
tumor (non-invasive). Cancer cells are not as specialized in terms of function in comparison 
to normal cells and therefore have the ability to divide uncontrollably. The transformation 
ability of a normal cell to a cancerous state is referred to as tumorigenesis, and it is 
facilitated by several cellular alterations which can be collectively described as “the 
hallmarks of cancer” (Fig. 5) [14].  
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       Figure 5: The hallmarks of cancer. The six hallmarks responsible for the transformation of 
a normal cell into the tumorigenic state [14]. 
 1.3.2 The hallmarks of cancer 
 In order for a normal cell to be transformed into the neoplastic state, the acquisition of six 
essential traits are required- as descibed below (Fig. 5).  
  1.3.2.1 Cancer cells- sustaining proliferative signaling 
 Normal cells control the production and release of growth-promoting signals that direct entry 
into and the progression through the cell’s growth-and-division cycle, thus ensuring homeostasis 
of cell number, tissue arichitecture and cellular function [14]. However, cancer cells have the 
ability to deregulate these signals and sustain chronic proliferation [14]. This may occur via the 
following mechanisms: cancer cells may produce their own growth-factor ligands, allowing them 
to respond via the expression of associated receptors, thus resulting in autocrine proliferative 
stimulation [14]. Alternatively, cancer cells may stimulate the growth of normal cells within the 
tumor-associated stroma by sending signals which in turn supply the cancerous cells with various 
growth factors [15, 16]. The levels of receptor protein present on the cancer cell surface may be 
elevated, rendering the cell hyper responsive to limiting amounts of growth factor ligand or 
structural alterations in the receptor molecule which render the same outcome [14]. Furthermore, 
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somatic mutations in the B-Raf protein and Phosphoinositide 3- kinase (PI3-kinase) isoforms 
may be responsible for the disruption of the Mitogen-activated protein (MAP) - kinase [17] and 
PI3K signalling pathways [18], respectively.  
1.3.2.2 Cancer cells- evading growth suppressors  
Cancer cells have the ability of inducing and sustaining growth-stimulatory signals, however in 
order for them to continuously grow and proliferate they must also be able to evade programs 
that negatively regulate cell proliferation; many of which depend on the actions of tumor 
suppressor genes [14]. The two key tumor suppressor genes: RB (retinoblastoma-associated) and 
p53 operate as central control nodes which govern the decision of cells to proliferate or, 
alternatively, activate cellular senescence and apoptosis [14].  
The essential function of the RB protein is to integrate extracellular and intracellular signals and 
in turn determine whether or not the cell qualifies to enter through the cell growth and cell 
division cycles [19-21]. Defective RB proteins therefore allow cancer cells to proliferate 
uncontrollably due to the lack of effective regulatory functions provided by the RB pathway 
[14]. p53 on the other hand, receives stress and abnormality signals through the intracellular 
sensors of the cell, which operate to halt further cell-cycle progression if excessive damage is 
caused [14]. p53 is a pro-apoptotic member which induces apoptosis in response to excessive 
damage to the genome and unfavourable cellular conditions. Cancer cells thereby have the ability 
to evade the action of p53, allowing the cells to avoid apoptosis and continue proliferating [22].  
1.3.2.3 Enabling replicative immortality 
Normal, non-cancerous cells are able to undergo a limited number of growth and division cycles 
due to the association with two key barriers to proliferation: senescence, the irreversible entrance 
into the nonproliferative but viable state, and crisis, which involves cell death [14]. However, 
tumorigenic cells are able to go through unlimited amounts of growth and division cycles thus 
exhibiting unlimited replicative potential via the transition of immortilization [14].   According 
to extensive lines of evidence, telomeres play a key role in immortilization, thus allowing for 
unlimited proliferation [23]. Telomeres are composed of several tandem repeats and are 
responsible for the protection of the ends of chromosomal DNA from damage such as end-to-end 
fusions [23, 24]. Telomerase is a specialised RNA dependent DNA polymerase that adds 
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telomere repeats to the ends of chromosomes, thereby preventing progressive telomere erosion 
from occurring [14]. Furthermore, the length of telomeric DNA governs the number of 
replicative cycles a cell can endure before erosion occurs and the protective function of the 
telomere has been lost [14]. Therefore, cancerous cells exhibit a significantly increased level of 
telomerase expression in comparison to the normal cell counterpart, thus reducing telomere 
shortening and allowing cells to continually proliferate by avoiding senescence and crisis or 
apoptosis [14].  
1.3.2.4 Activating tissue adhesion and invasion - key components of metastasis 
Tumor cells have the ability to selectively down-regulate and inactivate key cell-to-cell adhesion 
molecules (CAMs) such as E-cadherins [14]. This occurs as E-cadherin has the ability to form 
sheets of epithelial cells which are successfully kept in the quiescent state. Down-regulating the 
expression of E-cadherin allows cells to advantageously undergo tumorigenic transformation 
[25]. Specific proteases, such as collagenase are up-regulated in tumor cells, and this up-
regulation results in the degradation of the extracellular matrix (ECM), which in turn allows the 
cancerous cells to migrate to and invade secondary organs via the degradation of the basal 
lamina [26].  
1.3.2.5 Induction of tumor angiogenesis 
Tumor cells, like normal cells require a sustained source of nutrients and oxygen as well as the 
removal of metabolic waste and carbon dioxide in order to grow and survive effectively [14]. 
During tumor progression, normal quiescent vasculature is continuously producing new vessels 
in order to sustain the expansion of neoplastic growths, and this occurs as a result of the activated 
“angiogenic switch” [27]. The angiogenic switch is governed by angiogenic regulators which are 
signaling proteins that bind to stimulatory or inhibitory cell surface receptors. Therefore, in 
tumor cells, the expression of the angiogenic inducer known as vascular endothelial growth 
factor (VEGF) is deregulated allowing for the initiation and promotion of blood vessel formation 
[28, 29]. The promoted blood vessel formation creates the vasculature required by the tumor for 
nutrients and oxygen as well as waste disposal [29].  
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1.3.2.6 Resisting cell death/ apoptosis 
Apoptosis is referred to as programmed cell death and it acts as a natural barrier in the 
prevention and development of cancer. The apoptotic process is triggered in response to cellular 
stress and DNA damage, thereby maintaining a homeostatic environment within the cell [30]. 
Tumor cells are able to evade apoptosis and in this way, the tumor is able to extensively 
proliferate and progress [30]. The loss or the deregulation of the p53 tumor suppressor gene 
enables cancerous cells to avoid undergoing apoptosis and proliferate irrepressibly to form 
aggressive tumors [31]. Additionally, in the tumorigenic state the cells up-regulate the expression 
of anti-apoptotic factors and down-regulate the expression of pro-apoptotic factors in order to 
evade apoptosis [32, 33]. Evasion of apoptosis by tumor cells has been implicated as the key 
contributing factor in the aggressiveness of many cancer types [14], therefore it is crucial to 
target the mechanisms that govern this hallmark with respect to cancer therapeutics- this being 
the main focus of the present study.  
1.3.3 Apoptosis 
 Apoptosis is a morphologically and biochemically well-ordered process of cell death that occurs 
via a genetically determined cell suicide programme that serves an essential function in 
embryonic development and maintenance of tissue homeostasis [34]. In contrast, necrosis is a 
form of cell death that is considered as non-programmed. Apoptosis has been described by its 
induced morphological characteristics, including DNA fragmentation and chromatin 
condensation in early apoptosis and membrane blebbing, diminished membrane integrity and 
alterations in the structure of cytoplasmic organelles in late apoptosis [34, 35]. The apoptotic 
process is crucial from infancy throughout adulthood, but defects that arise in the apoptotic 
pathways are known to contribute to several human diseases, including autoimmune diseases, 
AIDS, neurodegenerative disorders and malignancy [36].  However, biochemical alterations to 
the apoptotic cell include activation of caspases, protein and DNA breakdown and phagocytosis 
as a result of membrane changes [37]. The membrane integrity of the cell is lost as it moves from 
an early to a late apoptotic phase, thus resulting in the package of the cellular contents into 
apoptotic bodies, stimulating phagocytosis of dead cells by macrophages without harming other 
cells (Fig. 6) [37]. Apoptosis can be induced by internal stimuli such as DNA damage and 
external stimuli such as oxidative stress [13]. The apoptotic machinery is composed of upstream 
12 
 
regulators and downstream effector components [30]. The regulators are divided into two key 
circuits; one receiving and processing extracellular death-inducing signals (the extrinsic 
apoptotic pathway) and the other pathway which senses and integrates a variety of signals of 
intracellular origin (the intrinsic pathway). Each of the above described pathways, result in the 
activation of the latent Cysteine- aspartic protease (caspase) 8 and 9, respectively [14]. The 
family of proteases is abundant but in particular to the apoptotic pathways, caspase 8, 9 and 10 
serve as initiator caspases and caspase 3, 6 and 7 function as the effector caspases [38]. Once 
activated, a cascade of proteolysis is initiated involving effector casapases which are responsible 
for the execution phase of apoptosis [14]. The intrinsic apoptotic pathway is widely implicated as 
the barrier to cancer pathogenesis [14].  
 
Figure 6: The morphological and biochemical alterations in cells undergoing apoptosis. 
Once apoptosis is induced, the cell begins to shrink and the DNA is fragmented. Thereafter, 
membrane blebbing occurs and at a later stage phosphatidylserine (PS) is exposed on the 
outer surface of the cell membrane. Through this process, dead cells can be recognised by 
macrophages, allowing phagocytosis of the resultant apoptotic cells or cell bodies 
(http://image.slidesharecdn.com/apoptosis-121108135829-phpapp01/95/apoptosis-3-
638.jpg?cb=1352383200).      
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1.3.3.1 Death receptor-mediated (extrinsic) pathway  
The extrinsic signalling pathway initiates apoptosis via transmembrane receptor-mediated 
interactions which involve death receptors of the tumor necrosis factor (TNF) receptor gene 
superfamily [39, 40]. Members of the TNF receptor family have a cytoplasmic domain made 
up of 80 amino acids and it is referred to as the “death domain” [41]. The death domain 
plays a role in transmitting the death signal from the cell surface to the intracellular 
signaling pathways [39]. Some of the well-characterized ligands and corresponding death 
receptors include Apo3L/DR3, Apo2L/DR4 and DR5, TNF-α/TNFR1 and FasL/FasR [41-
45]. However, the FasL/FasR and TNF-α/TNFR1 models best describe the sequence of 
events that define the extrinsic phase of apoptosis. In these two models, the FasR and 
TNFR1 receptors group and the homologous trimeric ligand FasL and TNF- α binds, 
respectively, upon binding, cytoplamic adaptor proteins are recruited exhibiting a 
corresponding death domain which binds to the receptor [39]. The binding of the Fas ligand 
to the Fas receptor results in the subsequent binding of the FADD adaptor protein and the 
binding of the TNF ligand to the TNF receptor resulting in the binding of the TRADD 
adaptor protein with additional recruitment of FADD and RIP [39]. FADD then associates 
with procaspase-9 through the dimerization of the death effector domain [39]. A death-
inducing signalling complex (DISC) is formed, leading to the activation of procaspase-8 via 
auto-catalysis (Fig. 7) [39]. Upon activation of caspase-8, the execution phase of apoptosis is 
triggered.  
The extrinsic pathway can also be inhibited by certain factors such as the c-FLIP protein 
which binds to FADD and caspase-8, rendering them ineffective. Another protein referred to 
as Toso is seen to inhibit caspase-8 processing, via the Fas-induced apoptotic pathway [39].  
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Figure 7: The two main apoptotic pathways by which programmed cell death occurs. 
(http://www.impactaging.com/papers/v4/n5/full/100459/Figure1.jpg). 
1.3.3.2 Mitochondrial-dependent (intrinsic) pathway 
The intrinsic signaling pathway initiates apoptosis via a diverse collection of non-receptor-
mediated stimuli which produce intracellular signals that act directly on cellular targets [39]. 
These events are mitochondrial-dependent. The non-receptor-mediated stimuli produced 
intracellular signals may act in either a negative or positive manner, with the negative 
signals involving the absence of certain growth factors, hormones and cytokines [39]. This 
can therefore lead to the failure in suppression of death programs, triggering apoptosis [39].  
Several stimuli which act in a positive fashion include radiation, toxins, hypoxia, 
hyperthermia, free radicals and viral infections [39]. These stimuli result in the change of the 
inner mitochondrial membrane leading to the opening of the mitochondrial permeability 
transition (MPT) pore, loss of mitochondrial transmembrane potential and the release of two 
main groups of pro-apoptotic proteins from the intermembrane space and into the cytosol 
[39].   The first group of proteins activate the caspase-dependent mitochondrial pathway and 
they consist of cytochrome c, Smac/DIABLO, and the HtrA2/Omi serine protease [39]. 
Cytochrome c in particular, binds to and activates Apaf-1 and procaspase-9 forming an 
apoptosome (Fig. 7) [46, 47]. The procaspase-9 protease forms a cluster, and activates 
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caspase-9. Smac/DIABLO and HtrA2/Omi promote apoptosis by inhibiting the Inhibitors of 
apoptosis proteins (IAP) activity [48, 49]. The second group of pro-apoptotic proteins are 
released from the mitochondria during apoptosis, this occurs as a late event after the cells 
have died [39]. These groups of proteins include AIF, CAD and endonuclease G [39].  AIF 
translocates to the nucleas causing DNA fragmentation and condensation of peripheral 
nuclear chromatin [50]. AIF and endonuclease G function in a caspase-independent manner. 
Furthermore, CAD is released from the mitochondria where it translocates to the nucleas in 
order to fragment DNA, after cleavage by caspase-3 [39].  
The dysregulation of these apoptotic pathways has been implicated in several pathological 
conditions such as cancer and neurodegenerative disorders as previously stated. Cancer is 
seen to show low levels of apoptosis thus allowing abnormal cellular proliferation and 
tumorigenesis- the main focus of the present study.    
1.3.4 Relationship between apoptosis and cellular proliferation  
Coordination and balance between apoptosis and cellular proliferation is crucial for tissue 
homeostasis and normal development in the adult [51].  Therefore apoptosis is responsible 
for the loss of damaged cells via the reduction in cell number, thus ensuring a balance in cell 
numbers [52]. Cell proliferation, differentiation and death are fundamental for the 
functioning of multicellular organisms and therefore several lines of evidence link the 
process of apoptosis and proliferation. Several genes including oncogenes, are involved in 
the regulation of the cell cycle as well as being pivotal to the induction of apoptosis and 
proliferation; such genes include c-fos, c-jun, c-myc and p53 [52]. Important for the 
association between cell death and cellular proliferation is the tumor suppressor gene- p53, 
whose essential role is to maintain genomic integrity by regulating cells in the G1-S and G2-
M checkpoints of the cell cycle (Fig. 8) [52]. This is done in order to prevent abnormal cells 
from progressing through the cell cycle, and this is achieved via the detection of 
unfavourable genomic alterations [53]. 
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Figure 8: Stages of the cell cycle. Phase 0/Gap 0 is the stage at which the cells are 
metabolically active but quiescent. In order for inactive quiescent cells to enter into the G1 
phase, stimulated entry by growth factors and nutrients must be employed in order to 
generate extracellular signals. Cells then progress to the S phase where they undergo DNA 
replication which permits entry into the G2 phase- in which cells increase in size as well as 
synthesize proteins required for the mitotic (M) phase. In the M phase the cells duplicate via 
mitosis to form identical daughter cells. There are 2 crucial check-points within the cell 
cycle that ensure the orderly progression of cells through the distinct phases in the cell cycle 
and these are the G1-S and G2-M check-points. 
(http://images.tutorvista.com/cms/images/123/cell-cycle-2.PNG) 
       p53 becomes activated in one of the following ways when an apoptotic promoting signal             
is detected; 1) activation of ARF or 2) inhibition of MDM2 [54]. Pro-apoptotic genes such 
as Bax and CD95 are activated upon p53 activation. p53 induces apoptosis via 
mitochondrial interactions that promote the release of cytochrome c which is a pro-apoptotic 
molecule [55]. When the Bax gene is directly activated by p53, the Bcl-2 oncogene becomes 
inhibited, thus hampering the inhibition of Smac- a pro-apoptotic IAP- neutralising 
molecule [55]. Hence, apoptosis is induced by the activation of a cascade of caspases, as a 
result of the interaction that occurs between Smac and cytochrome c (Fig. 9) [55].  
G2-M 
checkpoint 
G1-S 
checkpoint 
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Figure 9: The role of p53 in apoptotic induction. Once an apoptotic signal is detected, 
p53 becomes activated, subsequently activating Bax. This causes an activation of Smac via 
Bcl-2 inhibition. Consequently, inhibitors of apoptosis (IAPs) become inactivated. The pro-
apoptotic, cytochrome c molecule is then released from the mitochondrion upon detection of 
an apoptotic signal. Smac and cytochrome c interact in order to induce apoptosis via the 
intrinsic pathway. The apoptosis induction process is prevented if mutations in the p53 gene 
are present, thereby promoting the tumorigenic phenotype 
(https://webhome.weizmann.ac.il/home/ligivol/apoptosis_project/apoptosis.jpg).  
1.3.5 Relationship between apoptosis and tumorigenesis   
As previously mentioned, the occurrence and regulation of apoptosis relies exclusively on 
genes, thus making the process of cell death highly vulnerable to genetic mutations.  The 
deregulation or suppression of apoptosis therefore contributes to carcinogenesis and the 
disruption of homeostasis via the aberrant expression of specific genes. This therefore allows 
for an increase is cellular life span, growth-factor independent cell survival and ultimately 
permitting uncontrolled cellular proliferation. Three protein families responsible for these 
processes are discussed below.  
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1.3.5.1 Bcl-2 family of proteins 
This protein family is made up of 15 Bcl-2 family members, which include pro-apoptotic and 
anti-apoptotic proteins that are crucial for the regulation of apoptosis [56]. According to studies 
conducted, bcl-2 does not exhibit the behavioural characteristics of a normal oncogene; instead 
of disrupting normal proliferation controls, Bcl-2 promotes cell survival by blocking apoptosis 
[57, 58, 59]. Many cancer types have been characterised by the altered expression of the genes 
encoding for these proteins [13]. The over-expression of Bcl-2 has been shown to contribute to 
the evasion of apoptosis by breast, brain [60] and prostate [61] cancers. Further studies have 
suggested that over-expression of the Bcl-2 proteins by cells, allows for the acquired multi-drug 
resistant phenotype, thereby aiding cells in tumorigenesis [62].  
1.3.5.2 Tumor necrosis factor (TNF) family of proteins 
Tumor cells often avoid the death receptor-mediated (extrinsic) pathway that induces apoptosis 
as a result of resistance to key components that are involved in this cell death pathway. The 
caspase homolog; c-Flip is an inhibitor of the death receptor pathway and has therefore been 
implicated in the occurrence of a variety of cancer types [63]. These inhibitors compete with 
caspases for binding to FADD, thereby inhibiting apoptosis and resulting in the formation of a 
Fas-resistant tumor [63]. The resultant tumors benefit from this resistance by having the ability 
to evade apoptosis in the presence of the Fas-ligand [63]. The resistance to Fas enables cells to 
express the Fas ligand on the cell surface without inflicting any harm on themselves, thus 
enhancing tumor progression [64].  
1.3.5.3 Inhibitor of apoptosis (IAP) family of proteins 
The IAP family has been suggested to interact with certain caspases and inhibit their pro-
apoptotic function. Proteins that form part of the IAP family include: Survivin, cIAP1, cIAP2 
and XIAP [65]. The IAP proteins have been seen to interact with Smac/DIABLO and HtrA2, 
thus leading to the activation of caspases and the induction of pro-apoptotic events [65]. Little 
is known about the expression pattern of genes encoding IAPs in tumorigenic cells, however 
the dysregulation of this expression has been implicated in many cancer types. In particular, the 
over-expression of Survivin and XIAP have been found in non-small cell lung carcinomas [66] 
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and the over-expression of the IAPs such as Livin and Apollon have been identified in 
melanoma cells [67] and gliomas [68], respectively.   
1.3.6 The extracellular matrix (ECM) 
1.3.6.1 The family of laminins 
Laminins are non-collagenous glycoproteins with common as well as specific functions [69]. 
Laminins play a major role in the formation of the extracellular matrix (ECM), thus assisting in 
holding cells and tissues together [69]. The ECM is crucial in that it serves the principal 
function of supplying and co-ordinating signals that regulate efficient cellular functions, direct 
and control cell migration, ensure that the cells receive the adequate receptor-mediated 
provision of nutrients and facilitate cell-cell associations [70]. Furthermore, the ECM is 
composed of two essential domains, namely: the basement membrane and the condensed layer 
known as the matrix [71]. Other components that form the basement membrane are the 
proteoglycans, matrix metalloproteinases (MMPs) and a selection of glycoproteins such as 
integrins, elastin, fibronectins, collagens and specific to this study, the family of laminins [70, 
71].  
Laminin-1 is composed of three chains namely α-, β- and γ- chains (Fig. 10), which are 
constituted by three disulfide-linked polypeptides and assembled differentially to form 17 
heterotrimeric laminin isoforms [72]. The heterotrimeric laminin isoforms can bind several 
ECM components such as collagen, entactin, proteoglycans and integrins [72]. One of the most 
important functions of laminin is to interact with receptors which are anchored in the plasma 
membrane of cells adjacent to basement membranes [69].  However, laminins have also been 
identified to play key roles in processes such as adhesion [73], cell migration [74], neurite 
outgrowth [75], cell differentiation and proliferation [76] and tumorigenic processes such as 
metastasis and angiogenesis [77].   
As previously mentioned, laminins contain receptor- binding sites, one such receptor is the 37-
kDa/67-kDa non-integrin laminin receptor precursor/ high-affinity laminin receptor (LRP/LR) 
[78] - which is of particular importance to this study.  
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Figure 10: The structure of laminin-1. Laminins are composed of α-, β- and γ- 
chains which are stabilized by interchain disulphide bonds. Laminins serve to bind 
several ECM molecules such as collagen IV, heparin and entactin as well as a group of 
cell surface receptors (https://bshia13.files.wordpress.com/2009/05/laminin.jpg)  
1.3.7 The 37-kDa/67-kDa laminin receptor precursor/ high affinity laminin receptor 
(LR/LR) 
The 37-kDa/67-kDa laminin receptor (LRP/LR) is a non-integrin cell surface glycoprotein 
that interacts with several ECM proteins. More importantly, LRP/LR binds to its primary 
ligand laminin-1, with high affinity [79]. LRP/LR is a transmembrane receptor with a length 
of 295 amino acids and consists of three domains; the N-terminal intracellular cytosolic 
domain, the transmembrane domain and the C-terminal extracellular domain which contains 
binding sites for laminin-1, carbohydrates, elastin, prion proteins and IgG antibodies (Fig. 11) 
[80]. The 37-kDa LRP is thought to be the precursor of the 67-kDa high-affinity laminin 
receptor LR, however the exact mechanism by which the precursor forms the receptor is 
unknown [81]. Early studies speculate that this mechanism may entail the process of 
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homodimerization that occurs via several post-translational modifications [81], however when 
a yeast two hybrid study showed failure of LRP to interact with itself and dimerize, this study 
was disproved [82]. Additional studies have suggested the process of fatty acylation by fatty 
acids such as oleate or stearate as the key modification that results in the maturation of the 37-
kDa LRP into the 67-kDa LR form [83]. Recent studies have proposed the mechanism of 
SUMOylation of LRP as the modification that results in the maturation of the 37-kDa LRP 
into the LR form.  LRP is therefore a target for small ubiquitin-like modifier (SUMO) 
proteins that have the potential to form oligomeric chains [84, 85].  
When LRP/LR is found as a transmembrane receptor, it plays physiological roles in processes 
such as migration, cell adhesion, proliferation, and the maintenance of cellular viability [78]. 
However, LRP/LR can also be localised in the nucleus and cytosol where it is involved in the 
maintenance of nuclear structures and translational processes, respectively [86-91]. The 
receptor is seen to be overexpressed on the surface of tumorigenic cells such as cervical, lung 
,prostate, colon [92], breast, oesophageal [93] and liver cancer cells [94],  thus contributing to 
the process of cellular transformation in terms of tumor invasion and metastasis. Incubation of 
the above mentioned metastatic cancer cells with the anti-LRP/LR- specific antibody IgG1-
iS18 resulted in significant reductions in adhesion and invasion, the two crucial steps of 
metastasis [92-94]. LRP/LR has also been shown to play a role in angiogenesis, an important 
hallmark of cancer. When blood vessels were treated in vitro with the anti-LRP/LR- specific 
antibody W3, blood vessel formation was significantly impeded [95]. LRP/LR has been 
implicated as a key contributor to the pathogenesis of viral and bacterial infections [96], prion 
protein related diseases [97], neurodegenerative diseases such as Alzheimer’s disease [98-
102] as well as enhancing telomerase activity [103] through the overexpression of 
LRP::FLAG [104] which is seen to play a role in the progression of the above mentioned 
diseases [105] as well as chemotherapy resistance in some cancers.  
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Figure 11: Structural representation of the 37 kDa/ 67 kDa laminin receptor 
(LRP/LR). This transmembrane receptor consists of 295 amino acids and comprises three 
domains: the intracellular cytosolic N-terminal domain (blue), transmembrane domain 
(maroon) and the extracellular C-terminal domain (purple). The amino acid region 161-180 
serves as a binding site for laminin-1 and heparin and amino acid region 272-280 is the IgG 
antibody binding domain [80].  
1.3.8 LRP/LR and evasion of apoptosis 
LRP/LR plays a role in the maintenance of cell viability, as previously stated. Cancerous 
cells strive to avoid cell death and the overexpression of LRP/LR assists cancer cells in this 
regard by interacting with the Midkine protein- a growth factor that enhances cell migration 
and promotes cellular proliferation and survival [106]. The Midkine protein assists LRP/LR 
in binding to the nuclear envelope and chromatin during interphase of the cell cycle in order 
to stabilize chromosomes, thereby assisting in maintaining cellular viability [106]. Focal 
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Adhesion Kinases (FAKs) interact with LRP/LR as a result of the LRP/LR- laminin 
interaction [80]. This interaction activates survival pathways of PI3-kinase/AKT and 
MEK/ERK1/2 as well as the up-regulation of the anti-apoptotic Bcl-2 protein which is 
involved in both intrinsic and extrinsic pathways. This process inhibits apoptosis (Fig. 12B) 
[80]. LRP/LR up-regulation in cancer cells facilitates tumor enhancement and progression 
by promoting apoptotic evasion [107]. A study involving the use of small interfering RNAs 
(siRNA) directed towards the mRNA of the 37- kDa LRP in liver (Hep3b) cancer cells, 
confirmed the role played by LRP/LR in the inhibition of apoptosis [107]. Recent studies 
indicated that LRP/LR does indeed play a role in inducing apoptosis and this was observed 
by the down-regulation of LRP expression using siRNA-LAMR1 in breast and oesophageal 
[108], cervical (HeLa) and lung (A549) [109] as well as pancreatic (AsPC-1) and 
neuroblastoma (IMR-32) cancer cells [110] (Fig. 12A(D)).   
 
Figure 12A: The role of LRP/LR in tumorigenesis. A) Several cancer cells exhibit an 
over-expression of LRP/LR in comparison to their normal cell counterparts. B) Up-
regulation of LRP/LR in tumor cells facilitates an increased binding of the receptor to 
laminin-1 in the basement membrane (adhesion), leading to the activation of type IV 
 
 
24 
 
collagenase, triggering the degradation of type IV collagen in the basement membrane- 
therefore allowing tumor cells to invade organs (invasion). The key events in metastasis, 
adhesion and invasion are impeded upon blockage of LRP/LR with the anti-LRP/LR-
specific antibody IgG1-iS18. C) Increased levels of LRP expression have been implicated in 
the formation of endothelial tubes, thus suggesting that the receptor plays a pivotal role in 
tumor angiogenesis. D) Of particular importance to this study: Tumor cells survive by 
evading apoptosis; however the use of siRNA targeted to LRP/LR successfully induced 
apoptosis in certain cancer types by LRP down-regulation (Adapted from Jovanovic et al, 
2015 [80]).  
 
 
 
 
 
 
 
 
 
 
 
Figure 12B: Schematic representation of the role performed by LRP/LR in extrinsic 
and intrinsic apoptotic pathways. Specific trigger signals are required by each pathway to 
initiate an energy-dependent molecular cascade of events. The extrinsic pathway is activated 
through the binding of ligands to surface receptors and for the intrinsic pathway, internal 
threats result in the release of intracellular proteins. The executioner caspases are then 
Chemotherapy 
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activated, resulting in characteristic morphological features within the execution pathway. 
These include: cell shrinkage, formation of cytoplasmic blebs, chromatin condensation and 
apoptotic bodies. The binding of LRP/LR to laminin, activates the PI3K/Akt and 
Mek/Erk1/2 survival pathways, increasing Bcl-2 levels and inhibiting caspase-3 and 
caspase-8. There are several other pathways by which apoptosis can be induced that are 
caspase dependent, however only the extrinsic and intrinsic pathways have been depicted 
here. (Adapted from Jovanovic et al, 2015 [80])   
Due to the affirmation that LRP/LR plays a critical role in maintaining cellular viability, this 
receptor can therefore act as a target for the development of possible therapeutics for the 
treatment of cancer.  
1.3.9 RNA interference 
RNA interference/ silencing refers to a gene regulatory mechanism in which small, 20- to 
30- nucleotide noncoding RNAs and their associated proteins control the expression of 
genetic information [111]. RNA interference events have been described in the majority of 
eukaryotic organisms [112]. The gene silencing functions to limit the level of transcription 
by either suppressing transcription (by a process referred to as transcriptional gene silencing 
(TGS)) or by activating a sequence- specific process of RNA degradation (by a process 
referred to as posttranscriptional gene silencing (PTGS) or RNA interference (RNAi)) [112]. 
This mechanism of regulation is employed by small interfering RNAs (siRNAs), which are 
double stranded RNA (dsRNA) molecules that aid in the degradation of sequences that are 
complementary to and present in the target mRNA [113]. During the process of 
PTGS/RNAi, the dsRNA molecules, cleave the inducer molecules into smaller fragments, 
degrading the target mRNA molecules by serving as the activators and inducers of this 
process [112]. The process of RNAi controls many crucial processes such as tissue 
differentiation, heterochromatin formation, cell proliferation as well as cell growth however, 
if this process is dysregulated it can be linked to the formation of neurological disorders, 
cardiovascular disease and several cancer types [114].  
In order to assist in the effective functioning of the PTGS/RNAi process, two enzyme 
complexes, namely Dicer and RISC are of importance (Fig. 13) [115].  
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      Dicer is an enzyme that forms part of the RNase III nuclease family and it is involved in the 
initiation of the PTGS/RNAi process, while being highly specific for dsRNA [112]. 
Functionally, the dimeric Dicer folds onto dsRNA, cleaving it into short nucleotide duplexes; 
known as small interfering ribonucleic acids (siRNAs) of approximately 21-23 bp in length, 
with 3’ overhangs of 2-3 nucleotides as well as 5’-phospate and 3’-hydroxyl termini [116]. 
Research by Hammond et al, (2000) [115] indicated that targeting endogenous genes of 
Drosophila S2 cells in a sequence-specific manner could be achieved by transfecting these 
cells with dsRNA. Due to the inability of these cells to degrade the target mRNA when 
treated with Ca
2+
- dependent nuclease (able to degrade DNA and RNA), indicates that RNA 
is an essential component of the nuclease activity which leads to the degradation of the target 
mRNA [115]. This nuclease activity is referred to as the RNA-induced silencing complex 
(RISC).  
1.3.9.1 The mechanism of RNA interference  
Several aspects of the PTGS/RNAi machinery are unknown, however the mechanism has 
become evident and it is incorporated into three essential steps: 
Step 1 (RNAi initiating step): the RNA nuclease Dicer binds to a large dsRNA molecule and 
cleaves it into fragments that are 21-25 nucleotides in length [109]. These fragments are the 
siRNAs (Fig. 13A).  
Step 2 ( Effector step): the siRNAs join to the multinuclease complex: RISC. The siRNAs 
form double-stranded, duplexed structures consisting of 3’ two-nucleotide overhangs and 5’ 
phosphate termini, as previously described [117]. In this organisation, siRNA cannot be 
incorporated into RISC [117]. The siRNAs unwind and incorporate ATP in order to allow for 
the enzymatic activation of RISC zymogens. The outcome of this is the residing attachment of 
the most stable siRNA with the RISC complex (Fig. 13B) [118].  
Step 3 (Gene silencing step): this step is charaterised by the activated RISC complex 
accompanied by the bound, stable siRNA strand in cleaving the target mRNA (Fig. 13C) 
[112]. The target mRNA is understood to be endonucleolytically cleaved at the central and 
complementary region of siRNA, which is located 10 nucleotides upstream from the paired 
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nucleotide at the siRNA’s 5’ end [119]. Target mRNA cleavage can occur in the absence of 
ATP, but if ATP is present the cleaved products are released with greater efficiency [112].         
 
  
Figure 13: The mechanism of RNA interference. A) Dicer binds to and cleaves 
dsRNA into siRNA fragments. B) RISC incorporates siRNA and binds to 
complementary sequences of mRNA. C) After binding, the activated RISC facilitates 
the cleavage and degradation of target mRNA 
(http://eng.thesaurus.rusnano.com/upload/iblock/775/RNA-interference_1.jpg).  
1.3.9.2 Applications of RNA interference  
The process of RNAi has become popular in terms of being a key mechanism for future 
biological applications that can be easily applied [112]. RNAi technology has been 
proven to be useful in analysing the functions of several genes in a wide variety of 
A 
B 
C 
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organisms [112]. In one instance, chromosome I and III of C.elegans has been screened 
by RNAi to identify the genes involved in cell division and embryonic development [120, 
121], and whole genome screening by RNAi may become common in the near future. 
Additionally, RNAi may facilitate drug screening and development by identifying genes 
that can explain drug resistance or genes whose mutant phenotypes are enhanced by drug 
treatment, and in particular providing the modes of action of these therapeutic compounds 
[112]. Due to the gene specific features of RNA interference, it has gained an increasing 
amount of attention as a possible therapeutic with regards to gene-related ailments [122], 
such as viral-based infections, genetic and autoimmune diseases and in particular cancer. 
siRNA gene silencing in vitro is easily achievable, however, in vivo studies prove to be a 
continuous challenge mainly due to off-target effects that negatively impact healthy, 
normal cells. Although challenging, RNA interference-based therapeutics have been 
developed to treat HIV and the hepatitis virus [120] as well as neurodegenerative 
disorders and cancer [124].   
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Chapter 2: Rationale, Hypothesis, Aim and Objectives 
2.1 Rationale and research question 
The 37-kDa/67-kDa laminin receptor (LRP/LR) has been observed to be over-expressed in 
several tumor cell types in comparison to their normal cell counterparts. The over-expression of 
this receptor has been identified as a key factor in tumor progression via the maintenance of 
tumor cell viability. It is evident that LRP/LR plays a critical role in enhancing tumor cell 
viability as indicated by the reduction in cellular viability upon down-regulation of this receptor. 
According to previously published studies, it has been proven that siRNA-mediated down-
regulation of LRP/LR led to reductions in the viability of breast (MCF-7), oesophageal (MDA-
MB 231 and WHCO1) [108], lung (A549), cervical (HeLa), liver (Hep3B) [109], pancreatic and 
neuroblastoma [110] cancer cells via apoptotic induction. These findings encouraged the 
question whether down-regulation of the LRP/LR receptor via siRNA-mediated action will 
induce apoptosis in early (A375) and late (A375SM) stage malignant melanoma cells through the 
reduction in their viability, and to determine if apoptosis is the primary form of cell death 
responsible for the reduction in tumor cell viability. 
2.2 Hypothesis 
siRNA-mediated down-regulation of the LRP/LR receptor will significantly reduce the viability 
of early and late stage malignant melanoma cells via the induction of apoptosis.  
2.3 Aim 
To investigate how siRNA-mediated down-regulation of the 37kDa/67kDa laminin receptor 
(LRP/LR) influences the cellular viability of early (A375) and late (A375SM) stage malignant 
melanoma cells and to determine which mode of cell death is induced by this down-regulation.  
2.4  Objectives  
 To determine cell surface LRP/LR levels in the above-mentioned cell lines by flow 
cytometry (FACS analysis).  
 To determine endogenous LRP/LR levels in the above-mentioned cell lines by 
performing western blotting and densitometric analysis. 
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 To successfully down-regulate the expression of LRP/LR in the cell lines mentioned via 
cell transfection with siRNA targeted to LRP mRNA.  
 To detect siRNA-mediated LRP/LR down-regulation by use of western blotting. 
 To analyse the effect of siRNA-mediated down-regulation on the cellular viability of the 
above mentioned cell lines using MTT assays. 
 To assess the induction of any nuclear morphological changes upon siRNA treatment 
targeting LRP/LR in the afore-mentioned cell lines using immunofluorescence 
microscopy with the addition of the Airyscan processing tool.  
 To assess possible apoptosis-inducing effects of siRNA-mediated LRP/LR down-
regulation by use of Annexin-V-FITC/PI assays as well as caspase-3 assays.  
 To analyse the specific pathways utilised by the above-mentioned cell lines to undergo 
siRNA-assisted apoptotic induction by performing caspase-8 and caspase-9 assays. 
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Chapter 3: Materials and Methods 
3.1 Cell culture 
            3.1.1 Cell lines 
            The following cell lines used were commercially available and established (Ref. W-CJ-
140804-1): 
 A375 (ATCC® CRL-1619™): Human malignant melanoma- derived from a 54 
year old female and classified as early stage melanoma with low metastatic and 
invasive properties due to decreased levels of the extracellular matrix (ECM) 
glycoprotein, Tenascin (TN) [122] . 
 A375SM (ATCC® CRL-1619™): Human malignant melanoma- derived from a 54 
year old female and classified as late stage melanoma with high metastatic and 
invasive properties due to elevated expression levels of the extracellular matrix 
(ECM) glycoprotein, Tenascin (TN) [122]. 
 
3.1.2 Cell culture media and method of cultivation 
The base medium for these two cell lines is Dulbecco’s Modified Eagle’s Medium 
(DMEM)/ High Glucose. For complete growth media, the above-mentioned media was 
supplemented with: 
 
 10% Fetal bovine serum (FBS) - heat inactivated.  
 1% Penicillin/Streptomycin antibiotic. 
 
Both cell lines were cultivated in the media described above. The cells were cultured on 
cell culture plates or flasks in an incubator with a set temperature of 37ºC and 5% CO2 in 
order to mimic in vivo conditions. Cells were sub-cultured when a confluency of 90% 
was reached or twice a week. Seeding and sub-culturing involved the removal of the cell 
culture media and washing of the cells with 5 ml phosphate buffered saline (PBS) to 
remove the excess media. The adherent cells were detached using 1X Trypsin/EDTA and 
incubated for approximately 10 minutes and re-suspended in fresh media. 
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3.1.3 Cryopreservation and storage of cells  
           The process of cryopreservation involved cell detachment using 1X Trypsin/EDTA post 
washing of the cells with PBS. The cells were re-suspended in the full growth media and 
centrifuged at 1200 rpm for 10 minutes. The supernatant was discarded and the pellet was 
re-suspended in fresh warmed cell culture medium. Additionally, 10% FBS and 10% 
DMSO was added to constitute the specific freezing medium. Following re-suspension, 
cells in 1 ml aliquots were incubated overnight at -20 ºC prior to being incubated at -
70˚C. The cells were then transferred to and stored in liquid nitrogen until required.  
3.1.4 Thawing of cells 
In the case that a cryopreserved stock of cells was needed, 1 ml of fresh culture media 
was pre-warmed at 37ºC and used to thaw the 1 ml frozen cell stock. The resulting 
suspension was centrifuged at 1200 rpm for 10 minutes. The supernatant was discarded 
and the pellet re-suspended in fresh media containing an additional 10% FBS. The cells 
were left to attach, differentiate and grow at 37ºC as previously stated.  
3.1.5 Quantification of cultured cells 
In order to ensure that a constant number of cells were used to obtain a specific cell 
density for the experimental procedures, cell counting was performed on both cell lines, 
in order to allow for an effective comparison. The BIORAD TC20 cell counter was used 
to perform cell quantification and to observe percentage cell viability using the Trypan 
blue staining solution. Trypan blue in principal stains dead cells blue and the viable cells 
appear clear.  
The cells were washed with PBS, detached using 1X Trypsin/EDTA and then re-
suspended in the culture media. An aliquot of 10 µl cell suspension was combined with 
10 µl Trypan blue staining solution. Thereafter, 10 µl of the mixture was placed on the 
cell counting plate. Once cell quantification was complete the cells were diluted to a 
required density, using warmed cell culture media.  
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3.2 siRNA-mediated downregulation of the laminin receptor (LRP/LR) 
3.2.1 Materials 
 24-well and 6-well plates 
 Dharmacon™ ON-TARGETplus SMARTpool Human RPSA (targeted to 
LRP/LR)* 
 esiRNA-RLUC (employed as a negative control) 
 DharmaFECT® Transfection Reagent 
 MISSION®  esiRNA-RPSA (targeted to LRP/LR)* 
 MISSION®  esiRNA-RLUC (negative control)* 
 MISSION®  Transfection Reagent 
 Serum-free Opti-MEM® 
 
*: These treatments were used following the transfection procedure described in 
section 3.2.2 below for SDS-PAGE/ western blotting and MTT assays only; as a 
means of eliminating any off target effects that may arise upon transfection.  
 
             3.2.2 Transfection procedure 
Cells were seeded onto the appropriate plates at specific densities depending on the 
experiment or assay performed. The cells were left to grow overnight to a confluency of 
approximately 40-55% before transfection was performed. The target siRNA’s and the 
negative control siRNA’s were diluted in specified amounts of serum-free Opti-MEM® 
(as per Appendix A), prior to being added to the cells. The cells were further 
supplemented with the respective transfection reagent in order to facilitate the 
transfection procedure. The plates were then incubated at 37ºC for 72 hours to allow for 
the transfection to take place prior to the downstream experimental procedures. 
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3.3 Protein biochemistry 
3.3.1 Preparation of cell lysates 
     3.3.1.1 Materials 
 Cell scrapers 
 Phosphate buffered saline (1X PBS) 
 1X RIPA buffer (10mM Tris-Cl (pH 8), 10mM EDTA, 300mM NaCl, 1% sodium   
deoxycholate (DOC), 1% Triton-X, 0.1% SDS) 
3.3.1.2 Methodology 
The attached cells were washed with PBS and then incubated in 400 µl of RIPA buffer 
for 2 minutes, prior to cell detachment and membrane disruption using a cell scraper. 
The resulting cell suspension solution was incubated at 4ºC for 15 minutes, where after 
it was centrifuged at 14000 rpm for 3 minutes. The supernatant containing the 
extracted protein was retained and the pellet discarded. The supernatant was stored at -
20ºC and thawed at 4ºC when required.  
3.3.2 BCA™ assay for protein quantification  
3.3.2.1 Principle of the BCA™ protein assay  
The BCA™ protein assay was performed in order to successfully determine the 
presence of protein in preparation for western blotting. A serial dilution of bovine 
serum albumin (BSA) standards were prepared and a standard curve constructed in 
order to determine cellular protein concentration. This assay involves the reduction of 
Cu
2+
 to Cu
+
 by the peptide bonds present in the proteins thus producing a violet 
solution of bicinchoninic acid (BCA, 2, 2 –Bichinolin-4,4’-dicarbonicacid) as well as 
Cu
+
. The absorbance was measured at 562 nm in order to provide an estimation of the 
amount of protein present in the sample. 
3.3.2.2 Materials 
 96-well plate 
 Eppendorf tubes 
 Bicinchoninic Acid solution (BCA)  
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 Copper (II) sulfate solution 
 Bovine Serum Albumin (BSA) powder 
 ELISA plate reader 
 
3.3.2.3 Methodology 
Bovine serum albumin (BSA) standards in the following concentrations: 0, 0.2, 0.4, 
0.6, 0.8 and 1 mg/ml were prepared. Thereafter, 25 µl of each standard was loaded into 
separate wells of a 96-well plate in triplicate. Similarly, 25 µl of cell lysates obtained 
from section 3.3.1 were diluted (1:5) and added to the 96-well plate in duplicate. 
Subsequently, 4.9 ml of BCA reagent and 100 µl of copper (II) sulphate solution were 
combined and 200 µl of this solution was added to the wells containing the BSA 
standards as well as the cell lysates. The plate was incubated at 37˚C for 30 minutes 
and thereafter, the absorbance of the resulting solution was measured at 562 nm using 
an ELISA plate reader. In order to determine the concentration of the proteins, a 
standard curve was constructed. 
 
3.3.3 Sodium dodecyl sulphate- Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
3.3.3.1 Materials 
 Stacking Tris buffer (0.5M Tris, pH 6.8) 
 Separating Tris buffer (3M Tris, pH 8.8) 
 10% ammonium persulfate (APS) in distilled water 
 TEMED 
 Pre-stained protein molecular weight marker 
 2X loading buffer (100mM Tris/HCl pH 6.8, 4% SDS, 2% β-mercaptoethanol,   
20% glycerol, 0.02% bromophenol blue) 
 1X SDS running buffer (10% of 10X running buffer) 
 10X SDS running buffer (250mM Tris, 192mM glycine in distilled water, 10% 
SDS) 
 Gel casting apparatus 
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3.3.3.2 Methodology 
SDS-PAGE was employed in order to separate proteins in a lysate sample. This technique 
was performed before the detection of LRP/LR levels by use of western blotting. The 
lysate samples were heated in the presence of SDS, which allowed for the proteins to be 
denatured; however they were also subjected to β-mercaptoethanol which facilitated 
protein denaturation through the reduction of disulphide bridges situated within the 
proteins. SDS does not only allow for protein denaturation but it also imparts a uniform 
negative charge along the length of the proteins thereby allowing molecular weight to be 
the principal determinant in the separation procedure. The negatively charged proteins 
migrated towards the anode of the electrical field and the proteins were separated on the 
basis of molecular size by the use of a polyacrylamide gel. With respect to the present 
study, a 12% polyacrylamide gel was utilised. After the lysate samples were heated at 95ºC 
for 5 minutes in the loading buffer, 10µg of the samples were loaded on the gel. The gel 
was resolved at 200 V for 30-45 minutes.  
 
3.4 Western blotting and immunological detection of proteins 
 
3.4.1 Materials  
  Transfer buffer (20% methanol in 192mM glycine and 25mM Tris) 
  Blocking buffer (3% BSA in 1X PBS-Tween) 
  Wash buffer (0.1% Tween in 1X PBS) 
  Polyvinyldifluoride (PVDF) membrane 
  Whatman filter papers 
  100% methanol 
  Primary antibody (anti-LRP/LR specific antibody IgG1-iS18) solution 
  Secondary antibody (anti-human IgG-HRP conjugated antibody) solution 
  Conjugated primary antibody (mouse monoclonal anti-β-actin peroxidase) for detection   
of β-actin loading control 
  Chemiluminescent substrate 
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  Blotting device 
 
3.4.2 Methodology 
Endogenous cellular LRP/LR levels and LRP/LR levels in siRNA tansfected cells were 
determined by employing western blotting. The separated proteins were transferred to a 
PVDF membrane via electro-blotting. Whatman papers were soaked in transfer buffer for 5 
minutes while the PVDF membranes (cut to the dimensions of the SDS-PAGE gel) were 
soaked in methanol for 2 minutes and in transfer buffer for 5 minutes thereafter. The PVDF 
membranes were then placed between soaked Whatman papers that were assembled onto 
the electro-blotting device. The gels were placed on top of the membranes and electro-
blotting took place for 50 minutes at 300 V and 350 A. The membranes were then blocked 
for 1 hour using blocking buffer, followed by a 24 hour incubation of the membranes in 2 
µl primary antibody diluted in blocking buffer (1: 10 000). The membranes were washed 
three times in wash buffer (10 minutes each) and then incubated in 1.5 µl secondary 
antibody diluted in blocking buffer (1:5000) for 1 hour and 30 minutes. Three washes were 
performed as previously mentioned and 1 ml of the chemiluminescent substrate was then 
used to detect the Horseradish peroxidase (HRP) conjugated secondary antibody. 
Thereafter, the fluorescent light emission was captured and detected using the BIORAD 
Chemidoc apparatus in order visualise the proteins. 
 
It is important to note that the β-actin antibody, which is used to detect β-actin and thus 
serves as a loading control, is directly conjugated to HRP and therefore does not require a 
secondary antibody. Densitometry was performed in order to quantify total protein levels 
using the ImageJ™ software.  
 
3.5 Flow Cytometry (FACS analysis) 
 
3.5.1 Materials 
 1X Trypsin/EDTA 
 4% paraformaldehyde 
 Primary antibody (anti-LRP/LR specific antibody IgG1-iS18) 
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 Secondary antibody (anti-human phycoerythrin (PE)-coupled) 
 Anti-chloramphenicol acetyltransferase antibody (CAT) produced in rabbit- will be used 
as an effective negative control primary antibody 
 Allophycocyanin (APC)-coupled secondary antibody produced in goat and directed 
towards rabbit IgG- will be used as the secondary antibody for the negative control  
 PBS 
 
3.5.2 Methodology 
Fluorescence Activated Cell Scanning (FACS) is a quantitative, analytical technique for 
counting and examining cells by suspending them in a stream of fluid and passing them 
through an electronic detection apparatus. This technique was used to determine cell surface 
LRP/LR levels in the afore-mentioned cell lines. FACS employs the principal of 
immunodetection whereby primary antibodies that are recognised by specific fluorochrome-
coupled secondary antibodies are used for the detection of a target protein; in this case the 
LRP/LR receptor. The flow cytometer is comprised of an argon laser beam that helps in the 
differentiation between antibody-labelled cells and unlabelled cells, thus allowing for the 
quantified expression of target LRP/LR on the cell surface.  
The cells need to be in suspension in order for flow cytometry to be performed, hence the 
cells were detached using 1X Trypsin/EDTA and centrifuged for 10 minutes at 1200 rpm. 
The resulting pellet was fixed in 4% paraformaldehyde for 10 minutes at 4ºC. After fixation, 
two cell suspensions were prepared by re-suspending the cell pellets in PBS - one half of the 
cell suspension was labeled with the  primary IgG1-iS18 antibody (30 µg/ml) in PBS while 
the other half of the cell suspension was unlabeled (serving as a control). The cells were 
incubated overnight at 4ºC and then washed three times with PBS by centrifugation at 5000 
rpm for 5 minutes. Both cell pellets were re-suspended in PBS and the PE- coupled 
secondary antibody. The cell suspensions were allowed to incubate in the dark for 1 hour, 
thereafter the cell suspensions were washed 3 times in PBS as previously described and re-
suspended in PBS before flow cytometric analysis. The same procedure was followed in 
order to obtain results for the negative control; CAT bacterial protein, using the negative 
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control antibodies outlined in section 3.5.1 above. The unlabeled cells prepared were used as 
a control.  
3.6 Assessing cellular viability 
3.6.1 MTT assay   
  3.6.1.1 Principle of the assay  
This assay is a colorimetric assay that is used to determine the amount of cell survival in 
response to external treatments such as drugs or antibodies. The assay relies on the cleavage of 
mitochondrial tetrazolium salt (MTT), which is water-soluble and yellow in colour, by viable 
cells. The cleavage of MTT occurs via the mitochondrial succinate dehydrogenase (reductase) 
enzyme; present in the mitochondria of viable cells to produce water-insoluble purple formazan 
crystals (Fig. 14 a).    In non-viable cells, the mitochondrial succinate dehydrogenase enzyme 
becomes inactivated, thus the MTT salt is not converted into formazan crystals (Fig. 14 b). The 
measurement of the absorbance of the resulting formazan crystal solution indicates the 
percentage of cell survival. Lower absorbance values therefore correspond to enhanced levels 
of cell death/ non-viable cells due to lower levels of MTT cleavage. 
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a) Viable cells                                                      b) Non-viable cells 
 
 
 
 
 
 
 
 
 
Figure 14: The MTT cell viability assay. a) In viable cells the yellow MTT salt is converted to 
the purple formazan crystals by the action of mitochondrial succinate dehydrogenase. b) In non-
viable cells, the reductase enzyme is inactive; therefore MTT is not converted into formazan.                    
(Adopted from https://upload.wikimedia.org/wikipedia/commons/d/de/MTT_reaction.png) 
3.6.1.2 Materials 
 24-well plates 
 PBS 
 MTT (1 mg/ml) 
 Dimethyl sulfoxide (DMSO) 
 ELISA plate reader 
3.6.1.3 Experimental procedure 
Both malignant melanoma cell lines (A375 and A375SM) were allowed to grow and reach a 
density of approximately 1 x 10
5 
cells/ml and 100 µl of cells at this density were seeded per well 
prior to siRNA transfection. After transfecting the cells, they were incubated at 37˚C for 72 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide 
Mitochondrial Succinate 
Dehydrogenase  
MTT 
Formazan 
(E, Z)-5-(4, 5-dimethylthiazol-2-yl)-1, 
3-diphenylformazan 
Mitochondrial Succinate 
Dehydrogenase  
MTT 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide 
Formazan 
(E, Z)-5-(4, 5-dimethylthiazol-2-yl)-1, 
3-diphenylformazan 
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hours. Thereafter, a 1 mg/ml solution of MTT was dissolved in 1X PBS and added to each well, 
followed by a 2 hour incubation period at 37˚C. Post incubation, the MTT- containing medium 
was discarded from each well and the remaining formazan crystals were dissolved in 500 µl of 
DMSO. The absorbance of the resulting formazan solution was measured at 570 nm using an 
ELISA plate reader. Controls were prepared and these included: untreated cells, negative control 
siRNA treated cells and positive control protocatechuic acid (PCA) treated cells.   
3.7 Assessing nuclear morphological changes 
3.7.1 Confocal microscopy and Airyscan processing  
3.7.1.1 Materials 
 4% paraformaldehyde 
 PBS 
 1 µg/ml DAPI stain 
 Slides 
 Coverslips  
 Gelmount mounting fluid (Sigma-Aldrich) 
3.7.1.2 Methodology 
This technique was performed in order to assess the nuclear morphological changes that occured 
upon down-regulation of the LRP/LR receptor via siRNA action. In addition, the Airyscan 
detector was employed as it allows for efficient light collection and thus improved sensitivity, 
speed and resolution. Airyscan benefits the confocal laser scanning microscope by increasing its 
power, thus providing fast read out times and very low background noise.  
The cells were grown and allowed to reach a density of approximately 1x10
5 
cells/ml. At this 
density, 200 µl of cells were seeded onto coverslips prior to siRNA transfection. Thereafter, cells 
were washed with 500 µl 1X PBS for 1 minute and fixed in 1 ml 4% paraformaldehyde for 15 
minutes. This was followed by three 1X PBS washes and thereafter the cells were permeabilized 
by adding 2 ml 0.1%Triton-X into each well for 20 minutes, followed by two washes with 1X 
PBS. The cells were then treated with 2 µl of DAPI nuclear stain diluted in PBS (0.2 µl DAPI in 
4 ml PBS) for 8 to 10 minutes in the dark. The coverslips containing the DAPI-treated cells were 
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washed 8 times in PBS and thereafter, coverslips were mounted (with the cells facing down) onto 
a clean microscope slide using 40 µl of mounting fluid. The cells were stored at 4˚C after setting 
took place overnight, until visualisation using a confocal microscope with the addition of the 
Airyscan. The controls were as follows: untreated cells, siRNA-RLUC treated cells (negative 
control) and PCA (positive control).  
3.8 Assessing apoptotic induction 
3.8.1 Annexin V-FITC/PI assay 
3.8.1.1 Principle of the assay 
 This assay is dependent on the Annexin V intracellular protein binding to phosphatidylserine 
(PS) in a calcium-dependent manner. PS is normally only located on the intracellular leaflet of 
the plasma membrane in healthy cells but during early apoptosis, subsequent asymmetry of the 
membrane is lost and PS translocates from the intracellular membrane to the external leaflet (Fig. 
16).   Translocation of PS to the external leaflet enables the fluorochrome-labelled Annexin V to 
bind to the protein in the presence of calcium; hence Annexin V staining allows for measurement 
of translocated PS and therefore allows for the detection of apoptosis by flow cytometry. The 
red-fluorescent dye; Propidium Iodide (PI) binds to DNA by intercalating between the bases with 
little or no sequence preference and it was employed in this assay to distinguish between early 
apoptotic and late apoptotic or necrotic cells (Fig. 16). Therefore, apoptotic cells show green 
fluorescence, dead cells red and green fluorescence, and live cells little or no fluorescence.  
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        Figure 15: Principle of the Annexin V-FITC/PI assay. Cells undergoing apoptosis 
experience a membrane-flip reaction that exposes phosphatidylserine (PS) on the external 
leaflet of the plasma membrane. Annexin V conjugated to FITC binds to the exposed PS, 
and FITC allows for detection of apoptotic cells. PI is a viability dye that is used to 
distinguish between early and late apoptotic cells. (Adapted from 
http://www.lifesci.dundee.ac.uk/sites/www.lifesci.dundee.ac.uk/files/Annexin.pngandhttps://www.
google.co.za/search?q=annexin+VFITC/+7AAD+assay&biw=1280&bih=865&source=lnms&tbm=
isch&sa=X&ved=0ahUKEwiMmI3R887KAhUBshQKHZuhCvoQ_AUIBigB#tbm=isch&q=+anne
xin+VFITC%2F+7+AAD+assay+&imgrc=XRgS2Qa44nSqDM%3A)       
 3.8.1.2 Materials 
 PBS 
 Trysin/EDTA 
 Annexin V-FITC solution (Refer to Appendix A)  
 1X Annexin-binding buffer 
 Propidium Iodide 
               Live cells                           Early apoptotic cells             Late apoptotic/Necrotic cells 
Phosphatidyl serine AnnexinV 
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 Flow cytometer (BD Accuri™ C6 Cytometer) 
 
3.8.1.3 Experimental procedure  
 
The cells were grown and seeded to an approximate density of 1.8 x10 
6
 cells/ml and 
transfected with the previously mentioned siRNAs. Cells were harvested using 1X 
Trypsin/EDTA and then washed thrice with ice-cold PBS. Thereafter, the cell suspensions were 
centrifuged at 1500 rpm for 10 minutes. The supernatant was discarded and the pellet re-
suspended in 100 µl 1X annexin-binding buffer. Subsequently, 5 µl of Annexin V-FITC 
solution and 5 µl of PI viability dye was added to the prepared cell suspensions and incubated 
on ice for 15 minutes in the dark. The samples were then supplemented with 400 µl of ice-cold 
1X annexin binding buffer prior to flow cytometric analysis which was performed within 30 
minutes. Importantly, it must be noted that untreated cells, esiRNA-RLUC treated cells, and 
PCA treated cells were used as controls, as with the previously mentioned methods. The FL1 
laser detects the Annexin V-FITC staining and FL2 detects PI staining. The compensation and 
quadrants were set using the following controls: unstained cells, Annexin V-FITC stained cells, 
PI stained cells, cells stained with both Annexin V-FITC and PI, and PCA-treated cells stained 
with both Annexin V-FITC and PI.  
 
3.8.2 Caspase-3, -8 and -9 assays  
 
3.8.2.1 Principle of the assay 
The caspase-3, -8 and -9 assay is a colorimetric protease assay that relies on caspase-mediated 
hydrolysis of a chromophore known as para-nitroaniline (p-NA) that is coupled to a peptide  
substrate. These assays are capable of quantifying the enzyme activity of caspases that recognise 
the peptide substrate sequence Asp-Glu-Val-Asp p-nitroaniline (DEVD-p-NA) for caspase-3, Ile-
Glu-Thr-Asp p-nitroaniline (IETD-p-NA) for caspase-8 and Leu-Glu-His-Asp p-nitroaniline 
(LEHD-p-NA) for caspase-9. The substrates used in the assays are synthetic peptides labelled at 
their C-termini with para-nitroaniline (p-NA) and are designed to measure the activity of these 
caspases. The caspases cleave the peptide, thereby releasing the p-NA chromophore which 
possesses a high absorbance at 405 nm. The absorption of light by free p- NA can therefore be 
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quantified using microtiter plate reader at 405nm. The absorbance reading of p- NA from an 
apoptotic sample in comparison to an un-induced control allows for the determination of the fold 
increase in caspase activity and consequently the occurrence of apoptosis. 
  
3.8.2.2 Materials 
 1X Cell Lysis Buffer 
 5X Assay Buffer 
 Caspase-3, -8 and -9 Substrate (2.5 mg/ml)* (Refer to Appendix A)  
 Eppendorf tubes 
 96-well plates 
 Spectrophotometer 
3.8.2.3 Experimental procedure 
Cells were grown to an approximate density of 1.2 x10
6
 cells/ml and transfected with the 
respective siRNA. Thereafter, 1.2x10
6
 cells were pelleted by centrifugation at 1500 rpm for 10 
minutes and re-suspended in 100 µl ice-cold 1X cell lysis buffer and incubated on ice for 10 
minutes. The cells were then centrifuged for 5 minute at 10 000 x g and the supernatant was 
placed on ice. Following this, the protein concentration of the supernatant was determined by use 
of a BCA™ assay as previously described in section 3.3.2 and subsequently, 200µg of protein 
was prepared according to manufacturer’s instructions (appendix section). The prepared assay 
mixture for each sample was then added to appropriate wells of a 96- well plate and incubated 
for 2 hours at 37˚C. The absorbance was measured at 405 nm using an ELISA plate reader. In 
addition to untreated cells, esiRNA-RLUC treated cells and PCA treated cells were used as 
negative and positive controls, respectively. 
 3.9 Statistical evaluation 
3.9.1 Statistical significance using student’s t-test 
The two-tailed student’s t-test with a confidence interval of 95% was used as a means of 
analysing the data, with p-values of less than 0.05 being considered significant. The statistical 
analysis was performed using the Microsoft
® 
Excel statistical programme. 
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3.9.2 Analysis of Pearson’s Correlation Coefficient (r) 
Pearson’s correlation coefficient was also used to measure correlation between LRP/LR levels 
and cell viability as well as apoptotic induction. A positive coefficient is an indication of direct 
proportionality between the two variables and a negative coefficient implies inverse 
proportionality. Measured correlation values close to 1 signifies high positive correlation.   
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Chapter 4: Results 
4.1 Early and late stage malignant melanoma cells exhibit high LRP/LR levels on 
the cell surface. 
LRP/LR over-expression has been observed in several cancerous cell lines and it is seen 
to play a pivotal role in mediating metastasis, tumor angiogenesis and in the maintenance 
of cellular viability [78]. Therefore, cell surface LRP/LR levels of early and late stage 
malignant melanoma cells were determined in order to confirm its presence on the cell 
surface and to quantify the percentage of cells displaying cell surface LRP/LR within a 
specific cell population. This was achieved through flow cytometry. Figure 16 indicates 
that both malignant melanoma cell lines exhibit a high percentage of cells within the cell 
population that contain LRP/LR on the cell surface. The distinct shift between the peaks 
represents the characteristic changes in median fluorescence intensity occurring as a 
result of the treatment of the cancer cells with the anti-LRP/LR specific antibody IgG1-
iS18 and an appropriate secondary antibody, conjugated to a fluorochrome. In particular, 
97.40% of the early stage (A375) and 98.47% of the late stage (A375SM) malignant 
melanoma cells display LRP/LR on the cell surface, thus confirming the presence of this 
receptor on the surface of both cell lines.   
 
 
 
 
 
 
Figure 16: Detection of the 37kDa/67kDa laminin receptor LRP/LR levels on the surface of 
early (A375) and late (A375SM) stage malignant melanoma cells. The blue peak represents 
the cells that have not been labeled with antibodies, while the orange peak is representative of 
the cells stained with the goat anti-human phycoerythrin (PE)-coupled secondary antibody only 
and the red peak is indicative of the cells that have been stained with both the anti-LRP/LR 
Cell count 
Fluorescence Intensity (FL-2) 
       A375                                               A375SM 
 
Unlabelled 
 
PE only 
 
IgG1-iS18 and PE 
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specific antibody IgG1-iS18 and the afore-mentioned secondary antibody. The unlabeled control 
is included in order to confirm that the secondary antibody does not bind non-specifically, hence 
a minimal shift in fluorescence intensity is observed between the blue and orange peaks. The 
shift obtained between the blue and red peaks indicates the presence of LRP/LR on the cell 
surface of both cell lines. The above plots are indicative of an average of experiments performed 
in triplicate, with 20 000 cells counted per sample and the cells were analysed using filter 2 (FL-
2) which is specific for the PE-fluorochrome.  
The anti-CAT antibody which targets the chloramphenicol acetyltransferase (CAT) protein was 
used as the negative control. CAT is absent on the surface of mammalian cells. As anticipated, 
both cell lines showed a minimal to no shift in fluorescence intensity, thus indicating that the 
CAT protein was indeed absent on the surface of the malignant cell lines thus indicating that no 
non-specific binding occurred (Fig.17). 
 
 
                                                      
 
 
 
 
 
 
Figure 17: Determination of chloramphenicol acetyltransferase protein levels on the 
surface of early (A375) and late (A375SM) stage malignant melanoma cells. The black peak 
represents the unlabeled cells, while the orange peak is representative of the cells stained with 
the goat anti-rabbit allophycocyanin (APC)-coupled secondary antibody only and the pink peak 
is indicative of the cells that have been stained with both the anti-CAT primary antibody and the 
afore-mentioned secondary antibody. No distinct shift was observed between the black and 
orange peaks, thus indicating that the secondary antibody did not bind non-specifically. 
Furthermore, a minimal shift was observed between the black unlabeled peak and the peak 
representing the cells labeled with both primary and secondary antibodies. The above plots are 
indicative of an average of experiments performed in triplicate, with 20 000 cells counted per 
sample and the samples analysed using filter 4 (FL-4) which is specific for the APC-
fluorochrome.  
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4.2 Late stage malignant melanoma cells exhibit higher cell surface LRP/LR levels in 
comparison to the early stage malignant melanoma cells.  
The levels of cell surface LRP/LR within the cell population was also analysed, in addition to the 
percentage of cells within the given cell population that exhibit cell surface LRP/LR. This was 
done using flow cytometry, with the same concentration of  primary IgG1-iS18 antibody and PE-
coupled secondary antibody used to label the same number of cells (20 000) within a specific 
population of both cell lines over the same period of time. The differential expression of cell 
surface LRP/LR was indicated through the median fluorescence intensity (MFI) as seen in Table 
1. The late stage (A375SM) malignant melanoma cells display significantly higher cell surface 
LRP/LR levels (86%) in comparison to the early stage (A375) malignant melanoma cells as seen 
in Figure 18.    
Table 1: Median Fluorescence Intensity (MFI) values used to determine differential 
expression of LRP/LR on the surface of A375 and A375SM cancer cells.  
Cell Line  MFI of unlabeled 
cells (A) 
MFI of cells stained 
with IgG1-iS18 and 
PE-coupled 
secondary antibody 
(B)  
Difference in MFI 
values i.e. (B-A) 
A375 2053.67 10135.5 8081.83 
A375SM  1819.33 16833.5 15014.17 
      *All MFI values are representative of an average of experiments carried out in three 
biological repeats performed in triplicate.  
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Figure 18: Quantification of LRP/LR levels on the surface of early (A375) and late 
(A375SM) stage malignant melanoma cells by flow cytometric analysis.  The cells 
were labeled with primary IgG1-iS18 antibody and the anti-human PE-coupled secondary 
antibody. Analysis was performed on 20 000 cells per sample in triplicate and the median 
fluorescence intensity (MFI) was used as an indicator of differential cell surface LRP/LR 
expression for both cell lines. The MFI values presented in the last column of Table 1 
were used in the construction of the above graph. The MFI values for A375 was set to 
100% and the A375SM cells were found to have 86% more cell surface LRP/LR than the 
A375 cells. *p<0.05, **p< 0.01 ***p<0.0001 
 
4.3 Late stage malignant melanoma cells display significantly increased total LRP levels in 
comparison to the early stage malignant melanoma cells.  
 
As previously indicated, LRP/LR is not only expressed on the cell surface but it is also found in 
the nucleus, cytosol and perinuclear region. Therefore in order to determine total LRP/LR levels 
in both malignant cell lines under study, western blotting as well as densitometric analysis was 
performed. A western blot representing both LRP/LR and β-actin (Fig.19A) is shown with the 
latter being used as a loading control. The anti-LRP/LR specific antibody IgG1-iS18 was used to 
successfully detect the 37kDa laminin receptor precursor (LRP) form.  The western blots 
revealed that both A375 and A375SM malignant melanoma cells express LRP, however upon 
densitometric quantification the A375SM cells were seen to display 62.5% more total LRP in 
comparison to the A375 cells (Fig.19B).   
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A)                                                                                                                                  
 
 
 
 
              B) 
      
 
 
 
 
 
 
 
 
Figure 19: Western blot assessment of the relative expression of total 37kDa laminin 
receptor precursor (LRP) levels in early (A375) and late (A375SM) stage malignant 
melanoma cells. A) Anti-LRP/LR specific primary antibody IgG1-iS18 and HRP-coupled 
secondary antibody was used to detect and visualize total 37kDa LRP levels in both malignant 
cell lines. β-actin was used as the loading control. B) Densitometric analysis performed on these 
blots revealed that A375SM cells possess 62.5% more total LRP in comparison to A375 cells. 
The values obtained from quantification of LRP were an average of triplicate repeats. The 
resultant values were used in the construction of this graph and the values for A375 were set to 
100%. *p<0.05, **p< 0.01 ***p<0.0001 
A high, positive correlation was observed between cell surface and total LRP/LR levels prior to 
siRNA transfection (Table 2), thus indicating that the quantified cell surface LRP/LR levels can 
be responsible for the observed total LRP levels.   
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Table 2: Pearson’s correlation coefficient (r) between cell surface and total LRP levels 
prior to siRNA transfection. 
Cell Lines 
 
Correlation between cell surface LRP and 
total LRP levels prior to siRNA transfection 
(r-value) 
A375 0.98 
A375SM 0.65 
  
4.4 siRNA technology leads to successful down-regulation of LRP expression in early and 
late stage malignant melanoma cells.  
In order to determine the role of LRP/LR expression on the cellular viability of the cell lines 
under study, siRNA- mediated down-regulation of LRP was performed. Post transfection of the 
early (A375) and late (A375SM) stage malignant melanoma cells with the ON-TARGETplus 
Dharmacon Human RPSA siRNA (targeting the mRNA of the 37kDa LRP with higher 
specificity and potency through the action of 4 siRNAs), western blot analysis and densitometric 
quantification was performed. Densitometric analysis of the western blot signals revealed that 
LRP was successfully down-regulated in both A375 and A375SM cells (Fig. 20A and 20B) by 
transfection with the afore-mentioned siRNA. It was observed that siRNA-Human RPSA 
transfected A375 and A375SM cells exhibited a 77% and 72% reduction in LRP levels, 
respectively in comparison to the non-transfected cells whose LRP expression levels were set to 
100%.  In addition, the transfection of A375 and A375SM cells with the Mission esiRNA-RLUC 
(negative control siRNA) showed no significant down-regulation of LRP when compared to the 
non-transfected cells (Fig. 20A and 20B). The sequences of the above-mentioned siRNAs are 
provided in the appendix section.  
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Figure 20: Down -regulation of LRP expression in early (A375) and late (A375SM) stage 
malignant melanoma cells post siRNA transfection. A and B) Transfection of both A375 and 
A375SM cells with Dhatmacon Human- RPSA resulted in the significant down-regulation of 
LRP by 77% and 72%, respectively when compared to the non-transfected cells (set to 100%). 
Densitometric analysis also revealed a non-significant difference between the non-transfected 
and esiRNA-RLUC transfected cells. *p<0.05, **p< 0.01 ***p<0.0001, N.S.: P>0.05 non-
significant.   
A high correlation was observed between total LRP levels prior to and post Human Dharmacon 
RPSA transfection (Table 3), this is indicative of the success rate of transfection in both cell 
lines.   
Table 3: Pearson’s correlation between total LRP levels prior to and post Human 
Dharmacon RPSA transfection.  
Cell Lines Correlation between total LRP levels prior 
to and post Human RPSA transfection (r-
value) 
A375 0.95 
A375SM 0.97 
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4.5 siRNA-mediated down-regulation of LRP expression results in significantly reduced 
viability of early and late stage malignant melanoma cells.  
The observed down-regulation of LRP and the effect thereof on cellular viability was analysed 
by MTT assays. Post-transfection of the A375 and A375SM cells with the Dharmacon Human-
RPSA, resulted in a significantly reduced cellular viability in comparison to the non-transfected 
cells and the cells treated with the afore-mentioned negative control siRNA. A375 and A375SM 
cells treated with the Human-RPSA showed a 47% and 61% reduction in cellular viability, 
respectively, compared to the non-transfected cells whose cell viability was set to 100% (Fig.21).  
Moreover, no significant reduction in cellular viability was observed for both cell lines when 
treated with the negative control esiRNA-RLUC, compared to the non-transfected cells (Fig. 21). 
Protochatechuic Acid (PCA) is a known apoptotic inducer and was therefore used as a positive 
control throughout experimentation. 
                                                                                                                               
 
 
 
 
 
 
 
 
 
 
Figure 21: The effect of siRNA-mediated down-regulation on the cellular viability of early 
(A375) and late (A375SM) stage malignant melanoma cells. MTT assays were used to analyse 
the effect of siRNA transfections with the Human RPSA on the cellular viability of both cell 
lines under study. The A375 and A375SM cells treated with the Human RPSA siRNA displayed 
a significant reduction of 47% and 61% in cellular viability, respectively. Cells treated with the 
negative control siRNA-RLUC showed no significant difference in cellular viability  when 
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compared to the non-transfected cells of both cell lines. PCA was used as a positive control and 
the value for the non-transfected cells was set to 100% for both cell lines. The graph is 
representative of an average of experiments performed in triplicate. *p<0.05, **p< 0.01 
***p<0.0001, N.S.: p>0.05 non-significant.   
A high correlation was observed between the level of Human RPSA-mediated LRP down-
regulation in A375 and A375SM cells, and the Human RPSA induced decrease in cellular 
viability in both malignant melanoma cell lines (Table 4).   
Table 4: Pearson’s correlation analysis between levels of Human RPSA siRNA-mediated 
LRP down-regulation and reductions in cellular viability of early (A375) and late 
(A375SM) stage malignant melanoma cells.  
Cell Lines Correlation between Human RPSA-mediated LRP 
down-regulation and reductions in cellular viability (r-
value) 
A375 0.6 
A375SM 0.88 
 
4.6 Use of an alternative siRNA confirms that LRP down-regulation is responsible for 
reductions in cellular viability in both early and late stage malignant melanoma cells.  
In order to confirm whether the observed reduction in cellular viability  occurred as a result of  
Human RPSA siRNA- mediated down-regulation and not due to due to off-target effects, an 
alternative siRNA (esiRNA-RPSA) that targets a different region of LRP was utilized (refer to 
appendix for siRNA sequence). Western blot analysis and densitometric quantification revealed 
that early stage (A375) malignant melanoma cells showed a significant down-regulation of 55% 
in LRP expression (Fig. 22A and 22B). The late stage (A375SM) malignant melanoma cells 
exhibited a significant reduction in LRP expression by 50% in comparison to the non-transfected 
cells (Fig. 22A and 22B). Treatment of both cell lines, A375 and A375SM with the negative 
control siRNA (esiRNA-RLUC) displayed no significant difference in LRP expression when 
compared to the non-transfected cells. 
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Figure 22: Detection of LRP expression in early (A375) and late (A375SM) malignant 
melanoma cells after transfection with an alternative siRNA. A and B) Western blotting and 
densitometric quantification revealed that after transfection of the cells with esiRNA-RPSA, 
there was a significant reduction of 55% in LRP expression in the early stage malignant 
melanoma cells and a 50% reduction in LRP expression observed in the late stage malignant 
melanoma cells when compared to the non-transfected cells, which was set to 100% as seen on 
the graph. In addition, there was no significant difference seen in LRP expression between the 
cells treated with the esiRNA-RLUC (negative control siRNA) and non-transfected cells. β-actin 
was used as the loading control and the graphs are representative of an average of experiments 
performed in triplicate. *p<0.05, **p< 0.01 ***p<0.0001, N.S.: p>0.05 non-significant.  
High correlations were obtained between total LRP levels prior to and post esiRNA-RPSA 
treatment (Table 5), a similar result to the one observed for the Human RPSA siRNA.  
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Table 5: Pearson’s correlation between total LRP levels prior to and post esiRNA-RPSA 
transfection.  
Cell Lines Correlation between total LRP levels prior 
to and post esiRNA-RPSA transfection (r-
value) 
A375 0.99 
A375SM 0.82 
   
In order to assess the effects of esiRNA-RPSA-mediated LRP down-regulation on the cellular 
viability of A375 and A375SM cells, MTT assays were performed. A significant reduction in 
cellular viability in both malignant melanoma cell lines was observed post transfection with the 
alternative siRNA. It was found that A375 cells showed a 45% decrease in cellular viability after 
siRNA treatment, while the A375SM cells indicated a 29% reduction in comparison to the non-
transfected cells (Fig 23). In addition, upon treatment of both cell lines with the negative control 
siRNA (esiRNA-RLUC), no significant change in cellular viability was observed when 
compared to the non-transfected cells (Fig. 23). Only western blotting and MTT assays were 
performed using two siRNAs (DHARMACON Human RPSA and the Mission esiRNA-RPSA) 
in order to confirm that no off target effects took place. Both siRNAs, DHARMACON Human 
RPSA and Mission esiRNA-RPSA, indicated the same effects on cellular viability in both the 
cell lines under study (Fig.21 and Fig. 23). This therefore confirms that the specific targeting and 
down-regulation of LRP, reduces the cellular viability in the malignant melanoma cells being 
investigated. All subsequent experiments were performed with the DHARMACON Human 
RPSA and Mission esiRNA-RLUC.    
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Figure 23: The effect of esiRNA-RPSA - mediated LRP down-regulation on the cellular 
viability of early (A375) and late (A375SM) stage malignant melanoma cells. After treatment 
of the cells with esiRNA-RPSA, MTT assays were performed to assess the effect on cellular 
viability. A375 and A375SM cells showed reductions of 45% and 29% in cellular viability, 
respectively after being treated with esiRNA-RPSA. Non-significant differences were observed 
in the viability of cells post treatment with the negative control siRNA (esiRNA-RLUC) when 
compared to the non-transfected cells for both cell lines (set to 100%). PCA was used as the 
positive control and the graph is representative of an average of three repeats. *p<0.05, **p< 
0.01 ***p<0.0001, N.S.: p>0.05 non-significant.   
High correlations were observed between the level of esiRNA-RPSA-mediated LRP down-
regulation in A375 and A375SM cells, and the esiRNA-RPSA induced decrease in cellular 
viability in both malignant melanoma cell lines (Table 6).   
Table 6: Pearson’s correlation analysis between levels of esiRNA-RPSA-mediated LRP 
down-regulation and reductions in cellular viability of early (A375) and late (A375SM) 
stage malignant melanoma cells.  
Cell Lines Correlation between esiRNA-RPSA-mediated LRP down-
regulation and reductions in cellular viability (r-value) 
A375 0.7 
A375SM 0.9 
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4.7 siRNA-mediated down-regulation of LRP expression results in nuclear morphological 
changes suggesting the induction of apoptosis in early and late stage malignant melanoma.  
In order to examine the mode of cell death and possible induction of apoptosis post Human 
RPSA siRNA treatment, confocal microscopy with the addition of Airyscan processing 
(resolution: 140 nm) was performed to detect potential nuclear morphological changes. When 
comparing the nuclei of the non-transfected cells (Fig. 25A) to the Human RPSA siRNA treated 
early stage (A375) malignant melanoma cells, the treated cells displayed distinct nuclear 
morphological changes such as the formation of apoptotic bodies, nuclear shrinkage and 
membrane blebbing (Fig. 24C). Similarly, the comparison of nuclei of Human RPSA siRNA 
treated late stage (A375SM) malignant melanoma cells (Fig. 25C) to the nuclei of the non-
transfected cells (Fig.25A) revealed the presence of nuclear morphological changes such as 
nuclear shrinkage and membrane blebbing. In addition, treatment of both cell lines with the 
negative control esiRNA-RLUC did not result in nuclear morphological changes when compared 
to the non-transfected cells (Fig. 24B and 25B). PCA is known as the positive control and was 
used to study the nuclear morphological changes that occur under apoptotic conditions (Fig. 24D 
and 25D).  
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Figure 24: The effect of siRNA-mediated LRP down-regulation on nuclear morphology of 
early stage (A375) malignant melanoma cells. A) Non-transfected cells with normal rounded 
nuclei with uncompromised nuclear integrity. B) Cells treated with the negative control esiRNA-
RLUC showed nuclei with similar characteristics to the non-transfected cells. C) 
DHARMACON Human RPSA siRNA transfected cells displayed decreased nuclear integrity, 
membrane blebbing and the formation of apoptotic bodies (as shown by the white arrows) thus 
indicating the induction of apoptosis. D) 8mM PCA treated cells exhibited nuclei that have 
undergone membrane blebbing and apoptotic body formation (indicated by the white arrows). 
All images were obtained at a magnification of 63X with the addition of the Aryscan processing. 
                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                               
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Distinct changes in nuclear morphology in late stage (A375SM) malignant 
melanoma cells post siRNA-mediated LRP down-regulation. A) The nuclear integrity is 
maintained in the non-transfected cells as shown by the normal and rounded shape of the nuclei. 
B) Negative control esiRNA-RLUC treated cells showed no disruptions in nuclear integrity, as 
expected. C) DHARMACON Human RPSA siRNA transfected cells showed reductions in 
membrane integrity, nuclear shrinkage and membrane blebbing (indicated by the white 
arrows).D) Positive control PCA treated cells showed reductions in membrane integrity and 
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apoptotic body formation (shown by the white arrows). All images were obtained at a 
magnification of 63X with the addition of the Airyscan processing. 
4.8 Annexin V-FITC/PI assays indicated that siRNA-mediated down-regulation of LRP 
expression leads to apoptotic induction in both the early and late stage malignant 
melanoma cells.  
Confocal microscopy with the addition of Aryscan processing (resolution: 140 nm) suggested 
that siRNA-mediated LRP down-regulation in early (A375) and late (A375SM) stage malignant 
melanoma cells causes distinct changes in nuclear morphology that are specific to cells 
undergoing apoptotic induction. Therefore, to confirm that this crucial observation of apoptotic 
induction has indeed occurred in both of the malignant cell lines, Annexin V-FITC/PI assays 
were performed.  
Upon transfection of A375 cells with Human RPSA siRNA (Fig. 26), 91.4% of the cells 
underwent total apoptotic induction when compared to the untreated cells. Treatment of 
A375SM cells with Human RPSA siRNA resulted in 97.4% of cells experiencing total apoptotic 
induction in comparison to the untreated cells (Fig. 27). In addition, treatment of both malignant 
cell lines with the negative control esiRNA-RLUC did not result in apoptotic induction (Fig. 27 
and 28). PCA was used as the effective positive control and led to high percentages of total 
apoptotic induction in both cell lines; 98.3% in the A375 cells and 97.8% in the A375SM cells 
(Fig. 26 and 27).      
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Figure 26: Induction of apoptosis in early stage (A375) malignant melanoma cells after 
Human RPSA siRNA transfection. The non-transfected/untreated plot shows a majority of 
cells in the lower left quadrant (Q1-LL) as it is representative of normal living cells. Treatment 
of the cells with the negative control esiRNA-RLUC also resulted in the majority of the cells 
appearing in the lower left quadrant, while the transfection of the cells with Human RPSA 
siRNA led to 8.1% of cells undergoing early apoptosis, as shown by the cells in the lower right 
quadrant (Q1-LR), and 83.3% of cells undergoing late apoptosis- therefore a total of 91.4% of 
cells underwent apoptosis after Human RPSA transfection. PCA was used as the positive control 
and resulted in majority of the cells appearing in the lower right quadrant and the upper right 
quadrant (Q1-UR), which is representative of cells undergoing late apoptosis. The upper left 
quadrant (Q1-UL) represents cells undergoing necrosis. 20 000 cells were counted per sample. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 
 
 
Figure 27: Apoptotic Induction in late stage (A375SM) malignant melanoma cells after 
siRNA transfection. Majority of the cells in the untreated and esiRNA-RLUC treated plot 
appeared in the lower left quadrant, indicative of normal living cells. 67.9% of cells transfected 
with Human RPSA siRNA appeared to be undergoing early apoptosis as shown in the lower 
right quadrant, while 29.5% of transfected cells were observed as undergoing late apoptosis 
(upper right quadrant) - therefore a total of 97.4% of Human RPSA siRNA transfected cells 
underwent apoptosis. Cells treated with PCA, appeared mostly in the upper right quadrant, 
indicative of cells undergoing late apoptosis. 20 000 cells were counted per sample.  
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4.9 The level of apoptotic induction after siRNA-mediated LRP down-regulation is 
significantly increased in early and late stage malignant melanoma cells. 
The level of apoptotic induction occurring after treatment of early (A375) and late (A375SM) 
stage malignant melanoma cells with Human RPSA siRNA was quantified by combining the 
percentage values obtained for live cells, early and late stage apoptosis as well as necrotic cells 
for each treatment condition (Fig. 26 and 27) in triplicate. This was used as an indication of total 
apoptotic levels and it was observed that 7% and 76% of A375 cells underwent early and late 
apoptosis, respectively. In addition, 65% and 31% of A375SM cells underwent early and late 
apoptosis, respectively. A375 and A375SM cells underwent 61% and 78% more total apoptosis 
in comparison to the non-transfected cells, after Human RPSA siRNA transfection, respectively.    
 
Figure 28:  Total levels of apoptotic induction in early (A375) and late (A375SM) stage 
malignant melanoma cells after siRNA-mediated LRP down-regulation. Post transfection of 
cells with Human RPSA siRNA, 7% and 76% of A375 cells underwent early and late apoptosis, 
respectively. 65% and 31% of A375SM cells underwent early and late apoptosis, respectively. 
A375 and A375SM cells underwent 61% (***p=0.00025) and 78% (****p=0.00002) more 
apoptosis in comparison to the non-transfected cells, respectively. Total apoptotic levels post 
siRNA transfection was obtained from the Annexin V-FITC/PI assay plots and the resultant  
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values were used in the construction of this graph. The graph represents an average of 
experiments performed in triplicate. *p<0.05, **p< 0.01 ***p<0.0001  
A High correlation was observed between total LRP levels post Human RPSA treatment and 
total levels of apoptosis for both cell lines (Table 7).  
Table 7: Person’s correlation between total LRP levels post Human RPSA transfection and 
total levels of apoptosis.   
Cell Lines Correlation between total LRP levels post 
Human RPSA transfection and total levels of 
apoptosis (r-value) 
A375 0.7 
A375SM 0.8 
 
4.10 siRNA-mediated down-regulation of LRP expression leads to a significant increase in 
caspase-3 activity in both early and late stage malignant melanoma cells. 
In order to further confirm that LRP down-regulation results in the induction of apoptosis, 
caspase-3 activity assays were performed. It was observed that post transfection with Dharmacon 
Human RPSA, A375 and A375SM cells displayed a significant 4-fold and 3-fold increase in 
caspase-3 activity, respectively when compared to the non-transfected cells (Fig.29). In addition, 
treatment of both cell lines with the negative control Mission esiRNA-RLUC, showed no 
significant difference in caspase-3 activity when compared to the non-transfected cells which 
were set to 100% (Fig. 29).  
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Figure 29: Analysis of the effect of siRNA-mediated LRP down-regulation on caspase-3 
activity in early (A375) and late (A375SM) stage malignant melanoma cells. Caspase-3 
activity assay indicated that post transfection of cells with Human RPSA siRNA, A375 and 
A375SM cells showed a significant 4-fold and 3-fold increase in caspase-3 activity, respectively 
when compared to the non-transfected cells (which was set to 100%). A non-significant 
difference was observed when both malignant melanoma cell lines were treated with the negative 
control esiRNA-RLUC and compared to non-transfected cells. Protocatechuic acid (PCA) was 
used as the positive control. The graph is indicative of an average of experiments performed in 
triplicate. *p<0.05, **p< 0.01 ***p<0.0001, N.S.: p>0.05 non-significant   
A high correlation was obtained between total levels of LRP post Human RPSA transfection and 
the increases in caspase-3 activity after RPSA treatment, thus indicating the increase in apoptosis 
(Table 8).  
Table 8: Pearson’s correlation between total LRP levels post Human RPSA transfection 
and increases in caspase-3 activity after Human RPSA treatment. 
Cell Lines Correlation between total LRP levels post 
Human RPSA transfection and increases in 
caspase-3 activity after Human RPSA 
treatment (r-value) 
A375 0.63 
A375SM 0.9 
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4.11 A375 cells exhibit a significant increase in caspase- 8 activity after siRNA-mediated 
down-regulation of LRP expression. 
Caspase-8 activity assays were performed in order to further confirm that siRNA-mediated LRP 
down-regulation induces apoptosis in early (A375) and late (A375SM) stage malignant 
melanoma cells, and in addition to gain insight into whether or not the caspase-8 mediated 
extrinsic pathway is used by each of the cell lines under study to induce apoptosis post 
transfection with DHARMACON Human RPSA. Post transfection of both cell lines with Human 
RPSA, A375 cells showed a significant 66% increase in caspase-8 activity when compared to the 
non-transfected cells, which were set to 100% (Fig. 30).  No significant difference was observed 
in caspase-8 activity in A375SM cells treated with Human RPSA when compared to the non-
transfected cells. Moreover, the treatment of both cell lines with the negative control esiRNA-
RLUC resulted in no significant difference in caspase-8 activity, when compared to the non-
transfected cells (Fig. 30).   
 
 
 
 
 
 
 
 
 
 
 
Figure 30: The effect of siRNA-mediated down-regulation of LRP expression on caspase-8 
activity in early (A375) and late stage (A375SM) malignant melanoma cells. DHARMACON 
Huaman RPSA transfected A375 cells showed a significant 66% increase in caspase-8 activity, 
when compared to non-transfected cells (set to 100%). Treatment of A375SM cells with 
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DHARMACON Human RPSA showed no difference in caspase-8 activity by comparison to 
non-transfected cells. Treatment of both cell lines with the negative control esiRNA-RLUC 
resulted in no significant difference in caspase-8 activity when compared to non-transfected 
cells. PCA was used as a positive control. The graph is indicative of an average of experiments 
performed in triplicate. *p<0.05, **p< 0.01 ***p<0.0001, N.S.: p>0.05 non-significant   
4.12 A375SM cells show a significant increase in caspase-9 activity after siRNA-mediated 
LRP down-regulation.  
Caspase-9 activity assays were performed in order to establish whether early (A375) and late 
(A375SM) stage malignant melanoma cells use the caspase-9 –mediated intrinsic pathway to 
induce apoptosis after siRNA-mediated LRP down-regulation. A375SM cells show a significant 
3-fold increase in caspase-9 activity in comparison to the non-transfected cells, which were set to 
100% (Fig. 31). A non-significant difference was observed in caspaase-9 activity in A375 cells 
treated with Human RPSA by comparison to non-transfected cells. In addition, treatment of both 
cells lines with the negative control esiRNA-RLUC resulted in a non-significant difference in 
caspase-9 activity in comparison to the non-transfected cells (Fig. 31).  
    
 
 
 
 
 
 
 
 
 
 
Figure 31: The effect of siRNA-mediated down-regulation of LRP expression on caspase-9 
activity in early (A375) and late (A375SM) stage malignant melanoma cells. DHARMACON 
Human RPSA transfected A375SM cells showed a significant 3-fold increase in caspase-9 
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activity when compared to non-transfected cells (set to 100%). Treatment of A375 cells with 
DHARMACON Human RPSA showed no difference in caspase-9 activity by comparison to 
non-transfected cells. Both tumourigenic cell lines displayed no significant difference in caspase-
9 activity after treatment of cells with the negative control esiRNA-RLUC, and by comparison to 
non-transfected cells. PCA was used as a positive control. The graph is indicative of an average 
of experiments performed in triplicate. *p<0.05, **p< 0.01 ***p<0.0001, N.S.: p>0.05 non-
significant  
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Chapter 5: Discussion 
Cancer is seen as a global burden affecting both economically developed and developing 
countries. It is a disease that exhibits high incidence and mortality rates and due to the alarming 
statistics previously outlined in section 1.1, it remains crucial to continuously investigate 
possible therapeutic tools for this disease. LRP/LR is a key contributor in the promotion of the 
tumorigenic phenotype, enhancing tumor progression through processes such as metastasis, 
tumor cell proliferation, apoptotic evasion by cancer cells and the maintenance of tumor cell 
viability. Therefore, the use of RNA interference technology to down-regulate LRP expression 
has been deemed an effective means of hampering the maintenance of tumor cell viability and in 
particular siRNAs directed to LRP/LR of lung (A549), cervical (HeLa) liver (Hep3B), pancreatic 
(AsPC-1) and neuroblastoma (IMR-32) cancer cells has resulted in decreased viability of these 
tumourigenic cells. Each cancer type has its own characteristic behavior and therefore it is 
critical to examine the use of LRP-specific siRNAs on other cancer types- which has been 
investigated in this study.       
5.1 Analysis of the difference in cell surface LRP/LR levels between early and late stage 
malignant melanoma cells  
Flow cytometric analysis revealed that significantly high percentages of both early (A375) and 
late (A375SM) stage malignant melanoma cells display LRP/LR on the cell surface, however 
these percentages are representative of the percentage of cells within the population that contain 
a certain amount of LRP/LR on the cell surface. The actual LRP/LR expression levels present on 
the surface of both malignant melanoma cell lines was then further investigated and quantified 
using median fluorescent  intensity (Section 4.2, Table 1) and it was revealed that A375SM cells 
display significantly higher cell surface LRP/LR in comparison to A375 cells. As indicated by 
Munien et al. (2017) [136] A375SM cells have a higher adhesive and invasive potential in 
comparison to A375 cells and are therefore more dependent on LRP/LR to carry out certain 
cellular processes. It has been shown that Human umbilical vein endothelial (HUVE) cells [95], 
liver cancer cells [94], pancreatic and neuroblastoma cells [137] as well as colorectal cancer cells 
[138] display high levels of LRP/LR on the cell surface in comparison to the poorly invasive 
breast cancer (MCF-7) cells. These findings indicate that several cancer cell lines rely on 
LRP/LR to perform certain cellular processes. Therefore it could then be speculated that 
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A375SM cells rely more on LRP/LR to assist in other processes such as maintenance of cellular 
viability and evasion of apoptosis- two of several essential functions the LRP/LR transmembrane 
receptor may be responsible for.  
In addition, the bacterial protein chloramphenicol acetyltransferase (CAT) was used as the 
negative control as it is not present in eukaryotic cells. CAT was used as an IgG isotype and 
therefore served as a highly efficient control due to the non-significant shift in the percentage of 
cells expressing LRP/LR on the cell surface thus confirming the specificity and recognition of 
IgG1-iS18 for LRP/LR.  
5.2 Assessment of the difference in total LRP levels between early and late stage malignant 
melanoma cells 
LRP/LR is predominantly found as a transmembrane receptor however, as previously described 
it can also be found in other cellular locations. Therefore, in addition to the differences observed 
in cell surface LRP/LR levels between A375 and A375SM cells, total LRP levels were also 
determined. Quantification of total LRP levels between the two malignant melanoma cell lines 
included the presence of this receptor in the cytosol, nucleus, perinuclear region and also on the 
cell surface. Western blotting and densitometric analysis revealed that A375SM cells contain 
higher total LRP in comparison to the early (A375) stage malignant melanoma cells. The role of 
LRP/LR in the nucleus is to maintain nuclear structures and to complete translational processes 
in the cytosol [86-91], therefore the increased total LRP levels present in A375SM cells may 
indicate that, in comparison to A375 cells, this cell line could be highly dependent on LRP/LR to 
perform the aforementioned roles internal of the cell. The high correlation observed in Table 2 is 
crucial as LRP/LR present on the cell surface is predominantly implicated in the maintenance of 
cellular viability and apoptotic evasion [107], therefore total LRP levels can be used to assess 
cell viability and the induction of apoptosis.  
5.3 siRNA mediated down-regulation of LRP 
LRP was down-regulated via RNA interference using the siRNA called Dharmacon ON-
TARGET Human RPSA, in order to assess the effect of this receptor on cellular viability. The 
Human RPSA siRNA targets the mRNA of the 37kDa laminin receptor precursor (LRP) form, 
targeting both sense and antisense strands of the human LRP gene via the ON-TARGETplus 
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modification pattern to reduce off-target effects (sequence provided in appendix). Western 
blotting was used to detect down-regulated LRP levels with the use of the anti-LRP/LR specific 
antibody IgG1-iS18, which only effectively detects the 37kDa LRP. Treatment of A375 and 
A375SM cells with Dharmacon Human RPSA showed significant reductions in LRP expression, 
when compared to the non-transfected cells- thereby proving the efficiency of Dharmacon 
Human RPSA on LRP expression.  
Furthermore, A375 cells showed a greater reduction in LRP expression after Human RPSA 
transfection in comparison to the A375SM cells and this may be due to the fact that the A375SM 
cells had higher total LRP levels than A375 cells before siRNA treatment. With regards to the 
preparation of lysates, the same density of cells from both cell lines was treated with the same 
volume and concentration of Human RPSA siRNA. Therefore, it can be suggested that the 
volume of Human RPSA used was effective in targeting more LRP in A375 cells due to lower 
total LRP levels present in this cell line prior to siRNA transfection. It can therefore be said that 
the volume of Human RPSA was less effective in targeting LRP in A375SM cells due to higher 
total LRP levels prior to siRNA transfection. High total LRP levels before siRNA transfection, 
therefore leads to less LRP down-regulation post siRNA treatment and vice versa.  
The 37kDa LRP is the precursor of the 67kDa LR form, therefore reduced LRP expression 
would in turn result in the reduced maturation of the LR form through the post-translational 
modification known as fatty acylation [83]. However this maturation does not occur through 
direct transcription or translation and therefore as previously addressed, the Human RPSA 
siRNA specifically targets the 37kDa LRP as the 67kDa LRP is unable to be directly targeted.  
It is important to note that the negative control Mission esiRNA-RLUC was used to eliminate the 
effects of Dharmacon Human RPSA by  not targeting arbitrary genes within the cell. This 
negative control siRNA is also designed to exert minimal or no effect on cellular viability as well 
as have no significant effect on LRP expression in both A375 and A375SM cells (Fig 20 A and 
20B).  
As observed experimentally, Human RPSA siRNA is specific for LRP in relation to the negative 
control esiRNA-RLUC which had no effect on LRP expression. In order to confirm that this LRP 
down-regulation wasn’t due to off-target effects, an alternative siRNA called Mission esiRNA-
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RPSA was used to target the mRNA of the 37kDa LRP, in a similar manner to that of the 
Dharmacon Human RPSA. The Dharmacon Human RPSA siRNA is designed to specifically 
target four sequences within the 37kDa LRP mRNA, while esiRNA-RPSA targets nucleotides 
521-929 of the mRNA sequence (as per Appendix A). Treatment of A375 and A375SM cells 
with esiRNA-RPSA resulted in significant reductions in LRP expression, respectively. The high 
correlation obtained further confirms that higher total LRP levels before siRNA treatment results 
in less LRP down-regulation post siRNA transfection. 
The two siRNAs referred to above, yielded similar effects even though their target sequences 
differ. It can therefore be said that the results obtained upon treatment with Dharmacon Human 
RPSA are a direct outcome of LRP down-regulation. As previously mentioned, esiRNA-RLUC 
was again used as the negative control and no significant difference in LRP expression was 
observed when A375 and A375SM cells were treated with this negative control siRNA, therefore 
also proposing high specificity of esiRNA-RPSA for LRP.  
5.4 Relationship between LRP expression and the maintenance of cellular viability 
LRP/LR plays a crucial role in the maintenance of cellular viability, however in order to gain 
further insight into this role, siRNAs were used to down-regulate LRP expression and the effect 
thereof on the cellular viability of early and late stage malignant melanoma was evaluated using 
MTT assays. Treatment of A375 and A375SM cells with Dharmacon Human RPSA resulted in 
significant reductions in cellular viability, when compared to the non-transfected cells. The high 
correlations further confirm the essential role of LRP/LR in the maintenance of cellular viability 
as the down-regulation of this receptor results in significantly lowered cellular viability. 
Similarly transfection of A375 and A375SM cells with the alternative esiRNA-RPSA resulted in 
significant reductions in cellular viability, respectively when compared to the non-transfected 
cells. This observation coincides with that of the cells transfected with the Human RPSA siRNA, 
therefore providing evidence for the critical role of LRP/LR in the maintenance of cellular 
viability.  
In addition, upon treatment of A375 and A375SM cells with the negative control esiRNA-
RLUC, no effect on cellular viability was observed thus confirming the high efficacy of this 
negative control as well as confirming the specificity of the respective target siRNAs used in the 
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study. The cells were also treated with 8 mM protocatechuic acid (PCA) - which is a known 
apoptotic inducer and therefore used as the positive control in this study. After treatment of A375 
and A375SM cells with PCA, reductions in cellular viability were observed- parallel to that of 
the cells treated with Dharmacon Human RPSA and Mission esiRNA-RPSA, as predicted.  
Tumor progression is facilitated through the evasion of apoptosis and this occurs via the over 
expression of LRP/LR and the important role it expresses in the maintenance of cellular viability 
[78]. A proposed mechanism by which LRP/LR maintains cellular viability is through the high 
binding interactions with the multifunctional heparin binding protein known as Midkine [126]. 
The Midkine protein is classified as a growth factor and it assists LRP/LR in binding to the 
nuclear envelope and chromatin in order to stabilize the chromosomes and in turn maintain 
cellular viability [106]. Moreover, the Midkine protein is seen to be expressed at high levels in 
human carcinomas and therefore it is associated with several cellular processes such as cellular 
migration and proliferation as well as angiogenesis [126]. Khumalo et al, 2015 [108] and Chetty 
et al, 2017 [110] indicated that down-regulation of LRP/LR in breast and oesophageal, as well as 
pancreatic cancer and neuroblastoma cells respectively, resulted in reductions in cellular viability 
and in turn the induction of apoptosis. It can therefore be said that siRNA-mediated LRP down-
regulation may result in a reduction in the LRP/LR-Midkine interactions thus being responsible 
for the observed reductions in cellular viability. In addition, Lu et al, 2016 [127] showed that 
siRNA-mediated down-regulation of the 67LR in colon cancer cells resulted in an upregulation 
of the pro-apoptotic Bax protein and a reduction in the anti-apoptotic Bcl-2 protein which is 
favourable for anti-cancer treatment as the ability of the cancer cells to survive is decreased. 
Knowing this, it can be said that siRNA-mediated LRP down-regulation in early and late stage 
malignant melanoma cells results in an upregulation of specific pro-apoptotic proteins and a 
downregulationn in anti-apoptotic proteins.    
5.5 Effect of down-regulated LRP expression on the induction of apoptosis 
5.5.1 Nuclear morphological alterations  
In order to confirm that apoptosis was the form of cell death responsible for the observed 
reductions in cellular viability of A375 and A375SM cells post LRP down-regulation, confocal 
microscopy with the addition of Airyscan processing was performed. The two malignant 
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melanoma cell lines were treated with the Human RPSA siRNA, and after transfection, nuclear 
morphological alterations were highly evident- this included reduced membrane integrity in the 
form of apoptotic bodies, nuclear membrane blebbing as well as nuclear shrinkage- in 
comparison to the non-transfected cells. These changes were furthermore observed in the PCA 
treated cells (positive control), therefore suggesting that siRNA-mediated LRP/LR down-
regulation induces apoptosis. It has been found that LRP/LR is a component of the nuclear 
machinery of the cell and therefore due to the strong association of nuclear and perinuclear 
LRP/LR to histones- nuclear structures are maintained [128]. Therefore down-regulation of 
LRP/LR results in reduced nuclear integrity and altered nuclear morphology. These observable 
Human RPSA siRNA- induced changes to the nuclear integrity and morphology of A375 and 
A375SM cells are indicative of apoptotic induction [34, 35] in these two malignant melanoma 
cell lines. Furthermore, disruptions in the structure of cellular DNA is characteristic in cells 
undergoing apoptotic induction [129].It has previously been shown that siRNA-mediated down-
regulation causes morphological changes in breast and oesophageal [108], lung and cervical 
[109] as well as pancreatic cancer and neuroblastoma cells [110].  However, transfection of both 
malignant melanoma cell lines with the negative control esiRNA-RLUC showed no disruptive 
alterations in nuclear morphology, confirmed by similarities to the non-transfected cells.  
5.5.2 Confirmation of Apoptotic induction via Annexin V-FITC/PI assays 
Even though confocal microscopy indicated the occurrence of apoptosis in A375 and A375SM 
cells, further confirmation as well as quantification of apoptotic induction was required and this 
was achieved by performing the Annexin-V-FITC/PI assay. Induction of apoptosis results in 
reductions in cell membrane integrity as previously described as well as a membrane flip- 
reaction which impacts the phospholipid asymmetry of the cell membrane. This occurs by 
exposing the intracellularly –located phosphatidylserine (PS) on the outer cell membrane leaflet, 
allowing the binding of Annexin-V to the negatively charged PS when calcium is present [129]. 
Important to note, the Annexin-V protein is bound to the FITC fluorochrome therefore allowing 
for the PS to be detected through the binding of Annexin-V. However, the binding of Annexin-V 
does not allow for the differentiation between early and late stage apoptosis thus the Propidium 
Iodide (PI) viability dye is additionally used to achieve this. In particular, PI stain cannot pass 
through intact cell membranes and therefore it is only able to stain cells in the late 
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apoptotic/necrotic phase due to the cells in this phase undergoing membrane alterations. This 
therefore allows PI to stain the double stranded DNA located in the nucleus, excluding early 
apoptotic cells which lack the disrupted cell membrane.  
It was observed that the non-transfected cells and the cells treated with negative control esiRNA-
RLUC for both malignant melanoma cell lines displayed negative staining for Annexin-V, as 
majority of the cells were situated in the lower left quadrant of the Annexin-V-FITC/PI plots, 
which is representative of living cells. Subsequently, Human RPSA-treated and PCA- treated 
(8mM) A375 and A375SM cells portrayed positive staining for Annexin-V, therefore appearing 
in the lower and upper right quadrants of the plots. The distinct shift from negative to positive 
Annexin-V staining indicates that Human RPSA siRNA-mediated LRP down-regulation in both 
malignant melanoma cell lines triggers membrane integrity disruption, but in particular cell 
membrane blebbing, which is typical of cells undergoing apoptosis. This process of cell 
membrane blebbing exposes PS to the outer cell membrane leaflet, favoring the binding of 
Annexin-V, as previously described. After transfection of both malignant melanoma cell lines 
with Human RPSA, majority of the A375 cells experienced late apoptosis, whilst majority of the 
A375SM cells experienced early apoptosis. The early stage malignant melanoma cells 
predominantly underwent late apoptosis as they express less LRP, allowing more down-
regulation to occur. This in turn results in more cell death, and a higher number of cells entering 
the late stage of apoptosis. The late stage malignant melanoma cells primarily underwent early 
apoptosis and this is due to more LRP present in this cell line, therefore less down-regulation and 
cell death occurring. This signifies the extended rate of apoptotic induction in the A375SM cells 
as well as reduced toxicity brought about by siRNA-mediated down-regulation in this cell line in 
comparison to the A375 cells. 
It has been shown by Khumalo et al, 2015 [108], Moodley et al, 2013 [109] and Chetty et al, 
2017 [110] that several cancerous cell lines undergo apoptosis via the early and late apoptotic 
stages through siRNA-mediated LRP/LR down-regulation. Small percentages of both cell lines 
underwent necrosis after treatment (upper left quadrant). One possible explanation for this 
observation could be due to the 72-hour incubation or transfection period being too long, thus 
also applying to the necrotic cells observed for the non-transfected condition. However, this 
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would have to be further investigated by shortening the incubation or transfection period and 
analysing the resultant observable effects. 
5.5.3 Mechanistic molecular pathways of apoptosis 
Nuclear morphological studies using confocal microscopy along with Annexin-V-FITC/PI 
assays proved that LRP down-regulation via siRNA-mediated action leads to apoptotic induction 
in A375 and A375SM cells. In addition, caspase-3 assays were performed to further confirm the 
apoptosis inducing effects of siRNA-mediated LRP down-regulation. The effector caspase-3 has 
increased activity in cells that are actively undergoing apoptosis [131]. Consequently, post 
transfection of A375 and A375SM cells with Human RPSA, there was a significant increase in 
caspase-3 activity in both cell lines in comparison to the non-transfected cells. These results 
clearly indicate that siRNA-mediated LRP down-regulation induces apoptosis in the two 
malignant melanoma cell lines, possibly as a result of the inhibition of the above-mention 
LRP/LR-midkine interaction. The repeated observation of apoptosis induction as a result of 
LRP- down-regulation via siRNA action may also be as a result of the LRP/LR- focal adhesion 
Kinase (FAK) interaction. A study conducted by Sun, L. et al [132] showed that the binding of 
LRP/LR to laminin, allows for the interaction between LRP/LR and FAK to occur. FAK carries 
out protein-protein interaction adaptor functions at sites of cell adhesion, and therefore it is seen 
to play a direct role in tumor growth and survival by activating survival pathways PI3K//AKT 
and MAPK/ERK as well as up-regulating Bcl-2 and anti-apoptotic proteins (Fig.12B) [132]. 
Thereby it can be stated that siRNA-mediated LRP down-regulation in the current study may 
reduce the LRP/LR-FAK interaction, resulting in apoptotic induction. LRP/LR is furthermore 
known to play a role in the biogenesis of ribosomes by facilitating the maturation process of the 
21S pre-rRNA into the 18S rRNA, while associating with and acting as a component of the 40S 
ribosomal small unit and assisting in protein translation and synthesis [133, 134, 135]. Therefore 
the down-regulation of LRP/LR could moreover have an impact on ribosomal formation and in 
turn translation of proteins crucial in the proper functioning and survival of cells- thereby 
causing cell death.  
Furthermore, A375 cells exhibited a greater increase in caspase-3 activity, in comparison to the 
A375SM cells after Human RPSA transfection. This could be due to the early stage malignant 
melanoma cells having lower total LRP/LR expression levels therefore a higher chance of 
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subsequent down-regulation and in turn induction of apoptosis. Furthermore, this could be as a 
result of additional DNA damage occurring in the A375 cells upon Human RPSA transfection, in 
comparison to the A375SM cells.  
Caspase-3 cleaves internal cellular substrates in order to initiate the induction of apoptosis and it 
is therefore an effector caspase. The observed increase in caspase-3 activity post Human RPSA- 
mediated LRP down-regulation can only be an indication of the occurrence of apoptosis since 
caspase-3 is involved in both the intrinsic and extrinsic apoptotic pathways (Fig. 7). Caspase-8 
and caspase-9 activity assays were performed in order to evaluate which apoptotic pathways 
A375 and A375SM cells initiate in order to undergo apoptosis after Human RPSA-mediated 
down-regulation of LRP expression as different cancer cell lines may utilize different 
mechanistic caspase pathways to undergo apoptosis as shown by Khumalo et al, 2015 [108], 
Moodely et al, 2013 [109] and Chetty et al, 2017 [110]. It was observed that early stage 
malignant melanoma cells displayed a significant increase in caspase-8 activity after treatment 
with Human RPSA, in comparison to the non-transfected cells. The late stage malignant 
melanoma also displayed an increase in caspase-8, however it was non-significant. As previously 
described, caspase-8 is involved in the extrinsic death receptor- mediated pathway, therefore it 
can be said that A375 cells undergo apoptosis via the extrinsic pathway post Human RPSA 
siRNA LRP down-regulation.  
In addition, it was observed that Human RPSA treated A375SM cells exhibited a significant 
increase in caspase-9 activity, by comparison to the non-transfected cells. Caspase-9 is highly 
involved in the mitochondrial-dependent intrinsic pathway, thus suggesting that Human RPSA-
mediated LRP down-regulation in A375SM cells induces apoptosis via the intrinsic pathway. 
Both malignant melanoma cell lines undergo apoptosis via different apoptotic pathways, thus 
being suggestive of the importance of the differential interactions between LRP/LR expression 
and the ECM components, particularly laminin. In addition, as the malignant melanoma cells 
transition from early stage (less invasive) to the late stage (more invasive), there may also be a 
change in the expression levels of specific apoptotic proteins involved in the extrinsic and 
intrinsic apoptotic pathways, such that as the transition occurs, the proteins involved in the 
extrinsic pathway decrease and the proteins in the intrinsic pathway increase.  This may occur as 
apoptotic proteins can be subject to the extent of caspase-mediated cleavage, with the cleavage 
78 
 
of caspase substrates being linked to signature alterations of apoptotic cells [141]. However, to 
obtain more insight in this regard, further analysis of the apoptotic proteins involved in the 
regulation of caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway) should be 
investigated.  
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Chapter 6: Conclusion and Future work 
6.1 Conclusion 
The present study indicated that siRNA-mediated down-regulation of LRP expression 
significantly reduced the cellular viability of both the early (A375) and late (A375SM) stage 
malignant melanoma cells through the induction of apoptosis. In particular, apoptosis occurred 
via the extrinsic pathway in A375 cells and via the intrinsic pathway in A375SM cells. 
These significant findings demonstrate the important role played by LRP/LR in the maintenance 
of cellular viability and the evasion of apoptosis in both malignant melanoma cell lines. The 
specific siRNAs known to target LRP expression may be considered as a possible therapeutic 
tool for the treatment of both early and late stage malignant melanoma cells.      
6.2 Future Work 
The present study only focused on two malignant melanoma cell lines (early and late stage) and 
therefore several other cancer types remain to be investigated in terms of siRNA-mediated LRP 
down-regulation and cellular viability. Additional cell lines within a specific cancer type that are 
at different stages of their life cycle (i.e. early, middle and late) could be considered in order to 
determine at which stage siRNA-mediated LRP down-regulation is most effective at reducing 
cellular viability. In addition, dose and time- dependent studies could be investigated in order to 
determine optimal transfection periods as well as siRNA dosages. Further apoptotic studies could 
be performed in order to gain further insight into the regulation of the intrinsic and extrinsic 
pathways via analysis of apoptotic proteins such as Bcl-2 and Bax.    
LRP/LR plays several physiological roles in normal cells, and therefore it may be worthwhile to 
investigate the effects of siRNA action on LRP expression in normal cells. This should be 
investigated in order to determine if the down-regulation of LRP exerts a minimal or no effect on 
the functioning of normal cells and in turn to further the study using animal models such and 
nude mice in vivo. Therefore, future studies could explore the use of siRNAs together with anti-
LRP/LR specific antibodies to treat several tumor enhancing processes. Animal trials, if 
successful may lead to clinical trials, therefore allowing the effect of siRNA-mediated LRP 
down-regulation and anti-LRP/LR specific antibodies to be evaluated in the human body. 
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Chapter 7: Animal study to investigate the role of IgG1-Is18 as a potential 
therapeutic to reduce the metastatic potential of malignant melanoma 
The efficacy of the anti-LRP/LR specific antibody IgG1-iS18 as a therapeutic tool for the 
treatment of malignant melanoma, using an in vivo MF-1 nude mouse model.  
7.1 Rationale and research question 
LRP/LR has been seen to be over-expressed in numerous cancerous cells, including breast, 
colon, cervical, prostate and in particular early (A375) and late (A375SM) stage malignant 
melanoma cells thus promoting tumor progression. This over-expression promotes enhanced 
LRP/LR-laminin-1 interaction resulting in elevated tumor aggressiveness and enhanced 
metastatic potential (as described in section 1.3.7). A direct correlation between LRP/LR levels 
and the metastatic and invasive potential of cells has been observed [136] and according to 
Munien et al, 2017 [137], treatment of cells with the anti-LRP/LR specific antibody IgG1-iS18 
has led to a significant reduction in the adhesion and invasion of A375 and A375SM malignant 
melanoma cells in vitro. Therefore the aim of the present study was to further investigate the 
significance of blocking LRP/LR with the IgG1-iS18 antibody and if this will be effective in the 
treatment of malignant melanoma, in vivo, using a MF-1 nude mice model.  
7.2 Hypothesis 
Blocking LRP/LR with the IgG1-iS18 antibody will significantly reduce the metastatic potential 
of malignant melanoma and therefore aid in the treatment of this cancer type, in vivo.   
7.3 Aim  
To further investigate the significance of blocking LRP/LR with the IgG1-iS18 antibody and to 
investigate whether the antibody is effective in the treatment of malignant melanoma in vivo.   
 
7.4 Objectives 
1. To assess the efficiency of the IgG1-iS18 antibody for the treatment of malignant melanoma 
using nude mouse models. 
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2. To analyse the ability of IgG1-iS18 with respect to tumor cell shrinkage and reductions in 
tumor cell metastasis in vivo 
7.5 Materials and methods 
The MF-1 nude mice model was employed to investigate the response of the IgG1-iS18 antibody 
on malignant transformation, invasion and metastasis. In this model, the human late stage 
malignant melanoma cells (A375SM) were subcutaneously injected into immunocompromised 
mice that do not reject human cells (Animal Ethics Clearance Number (AESC No.) 2015-04-C).  
This model allows for the investigation of different therapeutic approaches on human cancers 
and it is effective as the actual human tumor tissue or cancer cell lines are used thus featuring the 
complexity of genetic and epigenetic abnormalities of the human tumor population as well as the 
ability to obtain experimental results within a few weeks from a human tumor biopsy [141].  
The experimental approach involved an initial pilot study (which is presented here) using MF-1 
nude mice in order to assess the feasibility of the experimental design for the full in vivo study.  
7.5.1 Preparation of late stage malignant melanoma cells 
The A375SM cells were detached using 1X Trypsin/EDTA and re-suspended in full growth 
medium (DMEM). Thereafter, the cells were pelleted by centrifugation at 1200 rpm for 10 
minutes and then washed in 1X PBS prior to a second round of centrifugation at 1200 rpm. The 
resultant pellet was re-suspended in 10 ml media; cell counted and added into separate eppendorf 
tubes at a density of 5x10
6
 cells/ml. The cells were then centrifuged, and the pellet re-suspended 
in 110 µl media. Prior to subcutaneous injection of the cells, 110 µl cold Matrigel was added to 
the media and cell mixture.     
7.5.2 Transplantation procedure 
The 9 subject mice were divided into three groups; with three mice each and then individually 
anesthetized with Isofor Infusion (Isoflurane-100%) and oxygen at 1,5 – 2 %  for approximately 
3 minutes or until un-conscious, prior to subcutaneous injection of the late stage malignant 
melanoma cells. The cell mixture (220 µl) was then drawn up into a syringe and carefully 
82 
 
injected into the flank/ hind leg region of each mouse using either a 25 or 27 gauge needle. The 
tumors were then allowed to establish for 3 weeks (Fig.32).  
7.5.3 Analysis of tumor formation  
The mice were monitored externally for tumour formation by visually observing the mice, 
weighing the mice as well as quantifying the size and volume of the tumour via 3D caliper 
measurements. This occurred over the 3 week induction period prior to the initiation of 
treatment.  
7.5.4 Treatment regime  
Once the mice had visible tumour formation, within the 3 week induction period, group 1 was 
treated with 0.885 mg/ml of the IgG1-iS18 antibody, group 2 was treated with the Phosphate 
Buffered Saline (PBS) vehicle control solution and the last group remained untreated. The IgG1-
iS18 antibody was administered at 2.5mg/kg body weight twice a week, intraperitoneally over a 
period of 4 weeks (Fig. 33) [142]. For the vehicle control, Phosphate Buffered Saline (PBS) was 
injected in the same manner as stated above. The injection volume was limited by possible 
toxicity of the substance and by the size of the mouse and was therefore kept to a treatment 
volume of less than 105 µl [143]. The intraperitoneal injection was performed by grasping the 
scruff of the neck and tail tightly and turning the mouse over so that the abdomen was exposed 
(Fig.33). The antibody was injected into the lower left or right quadrant so as to avoid hitting 
vital internal organs such as the bladder and liver. No anaesthetic was administered, and the 
chest movements of the mice were monitored to make sure the animal was comfortable. In 
addition, the tumour size was measured twice a week during the 4 week treatment period.    
 After the four week treatment period, all nine mice were euthenized with 0.5 ml euthenaze and 
assessed for internal and external tumor formation. The tumors were harvested, then weighed 
and the tumor volumes determined using the following formula: V= (Length x width x width)/ 2.  
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Figure 32: The injection procedure of the A375SM cells in MF-1 nude mice. The 
A375SM cells were pelleted at a density of 5x10
6 
cells/ml and prepared in 100 µl Matrigel 
before subcutaneous injection into the rear flank region of the 9 subject mice. The cells 
were injected and allowed to establish into tumors over a period of 3 weeks.  
 
 
 
 
 
 
 
 
 
Figure 33: The treatment procedure of the MF-1 nude mice model using the IgG1-
iS18 antibody. The IgG1-iS18 antibody was administered twice a week for 4 weeks 
intraperitoneally and tumor size was monitored.   
7.6 Results and Discussion 
The results of this pilot study indicated that three of the nine mice developed external tumor 
formation: one of the mice being from the untreated group with a tumor volume of 352mm
3
 and 
a weight of 0.77g. The other two mice were from the IgG1-iS18 treatment group, both tumors 
having a tumor weight of 0.2g and a tumor volume of 40mm
3 
and 63mm
3
, respectively (Table 8). 
Subcutaneous injection of the A375SM cells 
into the left rear flank region of the mouse  
Administration of the IgG1-iS18 
Antibody Intraperitoneally  
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When comparing the tumor formation from the two groups, untreated and treated, there was a 
tumor volume difference of 312mm
3
 and 289mm
3
,
 
respectively and a weight difference of 0.575g 
(Table 8). Due to the reduction in tumor weight and volume post treatment, it can be concluded 
that the IgG1-iS18 antibody may act as a possible therapeutic tool for the prevention or treatment 
of malignant melanoma. This however is currently being investigated by performing the full in 
vivo study with a total of 24 MF-1 nude mice, 12 receiving IgG1-iS18 antibody treatment and 12 
receiving the PBS vehicle control. Due to visible tumour formation in the mice and evident 
reductions in tumour volume upon antibody treatment, it can be stated that the parameters from 
the pilot study are favourable in order to perform the full study.   
Malignant melanoma is the most deadly form of skin cancer and if it is not treated in its early 
stages it can become fatal as it is able to metastasise to distant sites in the body. Therefore, 
directly targeting the overexpressed LRP/LR receptor in malignant melanoma cells with the anti-
LRP/LR specific antibody IgG1-iS18, may act as a highly effective treatment option as it is 
directed towards reducing metastasis via the LRP/LR- laminin interaction [136]. With regards to 
the treatment options available, IgG1-iS18 is more target specific to each cancer type in that it 
directly targets metastasis while having a limited effect on normal cells which is not the case in 
terms of chemotherapy.  
Obtaining favourable results in vivo will allow for further research on the antibody as a possible 
novel therapeutic option for the treatment of malignant melanoma, and that may involve clinical 
studies and trials on human patients. 
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Table 9: Summarized experimental parameters and outcomes observed in the pilot 
study MF-1 nude mice model.  
 Mouse 1 Mouse 2 Mouse 3 
Treatment group Untreated IgG1-iS18 antibody IgG1-iS18 antibody 
Density of cells 
injected (cells/ml) 
5x10
6 
5x10
6
 5x10
6
 
Induction period 
for Tumour 
formation (weeks) 
3 3 3 
Visual 
representation of 
tumor formation 
 
Surface view of 
tumor: 
 
 
 
 
 
Internal view of 
tumor: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Tumour volume 
(mm
3
) 
352 40 63 
Tumor volume 
difference 
---- 312 289 
Tumor weight (g) 0.77 0.2 0.2 
Tumour weight 
difference (g) 
---- 0.575 0.575 
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Appendix A 
Reagents and Materials 
 Media (DMEM)- GE Life sciences /Hyclone 
 BSA, Ethanol -VWR Life sciences 
 Matrigel Matrix- Corning  
 Molecular weight marker -New England Biolabs Inc. 
 penicillin/streptomycin, PBS, Opti-MEM -biowest/Gibco  
 Tween, DMSO, lysis buffer-Merck Millipore 
 Methanol, Paraformaldehyde -Associate chemical enterprise (ace) 
 MTT powder -Duchefa Biochemie  
 Trypsin/EDTA, Pen/Strep Amphoteracin B 100X -Lonza 
 Trypan Blue, PCA-Aldrich chemistry 
 HEPES – Thermo Scientific  
 FCS- Capricorn Scientific 
 L-glutamine, sodium pyruvate, non-essential amino acids, BCA reagents , APS, acrylamide, 
TEMED, fluoromount mounting fluid, SDS, Triton-X– Sigma Life science  
 PVDF membrane – Pall corporation  
 Chemiluminescent substrate, Cell counting slides - Biorad  
 Microscopy slides and coverslips – Labocare  
 24-well, 6-well and cell culture flasks – Corning Inc.  
 
Antibodies and siRNAs  
 IgG1-iS18 – Affimed Therapeutics  
 Anti-human IgG-HRP, anti-human PE, anti-rabbit APC– Abcam  
 Anti-β actin peroxidase, anti-CAT, DAPI, esiRNA-RPSA, esiRNA-RLUC, Mission 
transfection reagent – Sigma  
 Dharmacon (5nmol and 20nmol)- GE Life sciences (Dharmacon) 
 DharmaFect transfection reagent –GE Life sciences (Dharmacon)  
 
Kits  
 Annexin V-FITC/ PI kit – BD Biosciences 
 Caspase 3,-8 and -9 kits – Merck Millipore 
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Equipment list 
 Flow cytometer – BD Accuri C6  
 Confocal microscope – Zeiss LSM 710 3-channel (images were captured using the blue laser, 
63X magnification using Zen software and the Airyscan processing tool).  
 Laminar flow – Labotec  
 ELISA reader – Tecan (using Magellan software)  
 Centrifuge – Eppendorf 5417C  
 Pipettes and micropipettes – Eppendorf research  
 Gel casting and running apparatus – Biorad  
 Biorad TC20 Cell Counter- Biorad 
 pH meter – Eutech instruments 
 
Software 
 ImageJ 
 IrfanView 
 LSM Image Browser 
 
 
Table A1: Dharmacon™ ON-TARGETplus SMARTpool Human RPSA, Mission esiRNA-
RPSA and esiRNA-RLUC target sequences  
 
Name of siRNA 
(catalogue/reference 
#) 
Organism Target sequence 
ON-TARGETplus 
SMARTpool siRNA, 
RPSA 
1. J-013303-05 
 
2. J-013303-06 
 
3. J-013303-07 
 
4. J-013303-08 
Homo 
Sapiens 
 
 
 
CGACAUGAGUUGUACUUCU 
 
GAUUGCAUAUCAAAGCAUA 
 
GGUCAUGCCUGAUCUGUAC 
 
UAUCAUAAAUCUCAAGAGG 
Mission esiRNA-
RPSA 
Homo 
Sapiens 
CCTCTCACGGAGGCATCTTATGTTAACCTACCTACCATTGCGC 
TGTGTAACACAGATTCTCCTCTGCGCTATGTGGACATTGCCAT 
CCCATGCAACAACAAGGGAGCTCACTCAGTGGGTTTGATGTGG 
TGGATGCTGGCTCGGGAAGTTCTGCGCATGCGTGGCACCATTT 
CCCGTGAACACCCATGGGAGGTCATGCCTGATCTGTACTTCTA 
CAGAGATCCTGAAGAGATTGAAAAAGAAGAGCAGGCTGCTGCT 
97 
 
GAGAAGGCAGTGACCAAGGAGGAATTTCAGGGTGAATGGACT 
GCTCCCGCTCCTGAGTTCACTGCTACTCAGCCTGAGGTTGCAG 
ACTGGTCTGAAGGTGTACAGGTGCCCTCTGTGCCTATTCAGCA 
ATTCCCTACTGAAGACTGGAGCG 
 
Mission esiRNA-
RLUC 
 GATAACTGGTCCGCAGTGGTGGGCCAGATGTAAACAAATGAAT 
GTTCTTGATTCATTTATTAATTATTATGATTCAGAAAAACATGC 
AGAAAATGCTGTTATTTTTTTACATGGTAACGCGGCCTCTTCT 
TATTTATGGCGACATGTTGTGCCACATATTGAGCCAGTAGCGC 
GGTGTATTATACCAGACCTTATTGGTATGGGCAAATCAGGCAA 
ATCTGGTAATGGTTCTTATAGGTTACTTGATCATTACAAATAT 
CTTACTGCATGGTTTGAACTTCTTAATTTACCAAAGAAGATCAT 
TTTTGTCGGCCATGATTGGGGTGCTTGTTTGGCATTTCATTAT 
AGCTATGAGCATCAAGATAAGATCAAAGCAATAGTTCACGCTG 
AAAGTGTAGTAGATGTGATTGAATCATGGGATGAATGG 
 
Table A2: Transfection procedure using Dharmacon™ ON-TARGETplus SMARTpool 
Human RPSA and Mission esiRNA-RLUC  
 
Lypholized  Human RPSA siRNA (5 nmol/20 nmol) were reconstituted in 250 μl/1000 µl of 1X 
RNAse- free siRNA buffer before use, and esiRNA-RLUC (200 ng/ µl) was purchased 
reconstituted. The table below shows the amounts of siRNA and corresponding components used 
for transfections per well of a 6-well and 24-well plate. 
 
 6-well plate (Total 
volume of 2 ml) 
24-well plate (Total volume 
of 500 µl) 
Opti-MEM media for addition of 
siRNA (µl) 
190 µl 47.5 µl 
Human RPSA (µl) 10 µl 2.5 µl 
Opti-MEM media for addition of  
DharmaFect Transfection reagent 
(µl) 
190 µl 47.5 µl 
DharmaFect/ Transfection reagent 
(µl) 
10 µl 2.5 µl 
DMEM media (µl) 1595 µl 398.5 µl 
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Basic procedure followed: 
Reconstituted Human RPSA was added to the corresponding volume of Opti-MEM media in an 
Eppendorf tube. In a second Eppendorf tube, transfection reagent was added to the corresponding 
volume of Opti-MEM media. Both tubes were incubated for 5 minutes at room temperature and then 
the contents of both tubes were mixed together and the Human RPSA siRNA mixture was incubated 
for a further 20 minutes at room temperature. The suggested volumes of DMEM media were added 
into the 6-well/24-well plates containing the seeded cells and thereafter the resultant siRNA solution 
was added to the cells. The esiRNA-RLUC and esiRNA-RPSA siRNA solutions were prepared 
according to the table below.  
 
Table A3: Transfection procedure using Mission esiRNA-RPSA and esiRNA-RLUC  
esiRNA-RPSA (200 ng /µl) and esiRNA-RLUC (200 ng /µl ) are purchased reconstituted. The 
table below shows volumes of esiRNA and corresponding components used for transfections per 
well of a 6-well and 24-well plate. 
  
 6-well plate (total volume of 2 
ml) 
24-well  plate (Total volume 
of 500 µl) 
Opti-MEM media for addition of 
siRNA (µl) 
250 µl 50 µl 
esiRNA-RPSA or esiRNA-RLUC 
(µl) 
5 µl 1.5 µl 
Opti-MEM media for addition of 
Mission Transfection reagent 
(µl) 
250 µl 50 µl 
Mission Transfection reagent 
(µl) 
5 µl 1.5 µl 
DMEM media (µl) 1490 µl 397 µl 
 
Basic procedure followed: 
esiRNA-RPSA or esiRNA-RLUC was added to the corresponding volume of Opti-MEM media in an 
Eppendorf tube. In a second Eppendorf tube, transfection reagent was added to the corresponding 
volume of Opti-MEM media. Both tubes were incubated for 5 minutes at room temperature and then 
the contents of both tubes were mixed together. Thereafter, the suggested volumes of DMEM media 
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were added into the 6-well/24-well plates containing the seeded cells and the resultant siRNA 
solution was added to the cells. 
 
Table A4: Composition of the 12% polyacrylamide gels prepared and used for SDS-PAGE (per 
gel) 
 
 Separating gel Stacking gel 
Distilled water 2.15 ml 1.83 ml 
40% Acrylamide 1.5 ml 313 µl 
Separating Tris buffer 1.25 ml --- 
Stacking Tris buffer --- 313 µl 
10% SDS 50 µl 25 µl 
APS 50 µl 25 µl 
TEMED 2 µl 2.5 µl 
 
 
Table A5: Caspase-3, -8 and -9 Assay Mixture components 
The table below contains the components and volumes used in the preparation of the respective 
caspase-3, -8 and -9 assay mixtures prior to incubation in a 96-well plate for 2 hours at 37˚C. 
 
Sample 5x Assay 
Buffer 
Caspase-3, 
-8 or -9 
sample 
Inhibitor DI H2O Caspase-3, 
-8 or -9 
Substrate 
Total 
Volume 
Buffer 
Blank 
20 µl 0 µl 0 µl 80 µl 0 µl 100 µl 
Substrate 
Blank 
20 µl 0 µl 0 µl 70 µl 10 µl 100 µl 
Test 
Sample 
20 µl X µl 0 µl (70-X) µl 10 µl 100 µl 
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